Document:

Exhibit 10.2

 

PEET’S COFFEE & TEA, INC.

 

AMENDED AND RESTATED

2000 NON-EMPLOYEE DIRECTOR STOCK OPTION PLAN

 

Adopted November 1, 2000

Approved By Shareholders November 17, 2000

 

Amended and Restated on March 3, 2008

Amended and Restated on March 16, 2010

 

Amended and Restated on May 11, 2012

 

1.Purposes.

 

(a)Eligible
Option Recipients. The persons eligible to receive Options are the Non-Employee Directors of the Company.

 

(b)Available
Options. The purpose of the Plan is to provide a means by which Non-Employee Directors may be given an opportunity to benefit
from increases in value of the Common Stock through the granting of Nonstatutory Stock Options.

 

(c)General Purpose.
The Company, by means of the Plan, seeks to retain the services of its Non-Employee Directors, to secure and retain the services
of new Non-Employee Directors and to provide incentives for such persons to exert maximum efforts for the success of the Company
and its Affiliates.

 

2.Definitions.

 

(a)“Affiliate”
means any parent corporation or subsidiary corporation of the Company, whether now or hereafter existing, as those terms are defined
in Sections 424(e) and (f), respectively, of the Code.

 

(b)“Annual
Grant” means an Option granted annually to all Non-Employee Directors who meet the criteria specified in subsection
6(b) of the Plan.

 

(c)“Annual
Meeting” means the annual meeting of the shareholders of the Company.

 

(d)“Board”
means the Board of Directors of the Company.

 

(e)“Code”
means the Internal Revenue Code of 1986, as amended.

 

(f)“Common
Stock” means the common stock of the Company.

 

(g)“Company”
means Peet’s Coffee & Tea, Inc., a Washington corporation.

 

    	1

    	 

    
 

 

(h)“Consultant”
means any person, including an advisor, (i) engaged by the Company or an Affiliate to render consulting or advisory services and
who is compensated for such services or (ii) who is a member of the Board of Directors of an Affiliate. However, the term “Consultant”
shall not include either Directors of the Company who are not compensated by the Company for their services as Directors or Directors
of the Company who are merely paid a director’s fee by the Company for their services as Directors.

 

(i)“Continuous
Service” means that the Optionholder’s service with the Company or an Affiliate, whether as an Employee, Director
or Consultant, is not interrupted or terminated. The Optionholder’s Continuous Service shall not be deemed to have terminated
merely because of a change in the capacity in which the Optionholder renders service to the Company or an Affiliate as an Employee,
Consultant or Director or a change in the entity for which the Optionholder renders such service, provided that there is no interruption
or termination of the Optionholder’s service. For example, a change in status without interruption from a Non-Employee Director
of the Company to a Consultant of an Affiliate or an Employee of the Company will not constitute an interruption of Continuous
Service. The Board or the chief executive officer of the Company, in that party’s sole discretion, may determine whether
Continuous Service shall be considered interrupted in the case of any leave of absence approved by that party, including sick leave,
military leave or any other personal leave.

 

(j)“Director”
means a member of the Board of Directors of the Company.

 

(k)“Disability”
means the inability of a person, in the opinion of a qualified physician acceptable to the Company, to perform the major duties
of that person’s position with the Company or an Affiliate of the Company because of the sickness or injury of the person.

 

(l) “Employee”
means any person employed by the Company or an Affiliate. Mere service as a Director or payment of a director’s fee by the
Company or an Affiliate shall not be sufficient to constitute “employment” by the Company or an Affiliate.

 

(m)“Exchange
Act” means the Securities Exchange Act of 1934, as amended.

 

(n)“Fair
Market Value” means, as of any date, the value of the Common Stock determined as follows:

 

(i)If the
Common Stock is listed on any established stock exchange or traded on any Nasdaq market, the Fair Market Value of a share of Common
Stock shall be the closing sales price for such stock (or closing bid, if no sales were reported) as quoted on such exchange or
market (or the exchange or market with the greatest volume of trading in the common stock) (such exchange or market, the “Applicable
Market”) on the day of determination.

 

(ii)In the
absence of such markets for the Common Stock, the Fair Market Value shall be determined in good faith by the Board.

 

(o)[INTENTIONALLY
DELETED]

 

(p)“IPO
Date” means the effective date of the initial public offering of the Common Stock, which was January 25, 2001.

 

    	2

    	 

    
 

 

(q)“Non-Employee
Director” means a Director who is not an Employee.

 

(r)“Nonstatutory
Stock Option” means an Option not intended to qualify as an incentive stock option within the meaning of Section
422 of the Code and the regulations promulgated thereunder.

 

(s)“Officer”
means a person who is an officer of the Company within the meaning of Section 16 of the Exchange Act and the rules and regulations
promulgated thereunder.

 

(t)“Option”
means a Nonstatutory Stock Option granted pursuant to the Plan.

 

(u)“Option
Agreement” means a written agreement between the Company and an Optionholder evidencing the terms and conditions
of an individual Option grant. Each Option Agreement shall be subject to the terms and conditions of the Plan.

 

(v)“Optionholder”
means a person to whom an Option is granted pursuant to the Plan or, if applicable, such other person who holds an outstanding
Option.

 

(w)“Plan”
means this Peet’s Coffee & Tea, Inc. 2000 Non-Employee Director Stock Option Plan, as amended and restated from time
to time in accordance with the terms hereof.

 

(x)“Rule
16b-3” means Rule 16b-3 promulgated under the Exchange Act or any successor to Rule 16b-3, as in effect from time
to time.

 

(y)“Securities
Act” means the Securities Act of 1933, as amended.

 

3.Administration.

 

(a)Administration
by Board. The Board shall administer the Plan. The Board may not delegate administration of the Plan to a committee.

 

(b)Powers of
Board. The Board shall have the power, subject to, and within the limitations of, the express provisions of the Plan:

 

(i)To determine
the provisions of each Option to the extent not specified in the Plan.

 

(ii)To construe
and interpret the Plan and Options granted under it, and to establish, amend and revoke rules and regulations for its administration.
The Board, in the exercise of this power, may correct any defect, omission or inconsistency in the Plan or in any Option Agreement,
in a manner and to the extent it shall deem necessary or expedient to make the Plan fully effective.

 

(iii)To amend
the Plan or an Option as provided in Section 12.

 

(iv)To terminate
or suspend the Plan as provided in Section 13.

 

    	3

    	 

    
 

 

(v)Generally,
to exercise such powers and to perform such acts as the Board deems necessary or expedient to promote the best interests of the
Company that are not in conflict with the provisions of the Plan.

 

(c)Effect of
Board’s Decision. All determinations, interpretations and constructions made by the Board in good faith shall not be
subject to review by any person and shall be final, binding and conclusive on all persons.

 

4.Shares Subject to the Plan.

 

(a)Share Reserve.
Subject to the provisions of Section 11 relating to adjustments, the Common Stock that may be issued pursuant to Options shall
not exceed three hundred thirty thousand (330,000) shares of Common Stock (the “Reserved Shares”). As of each Annual
Meeting, beginning in 2002, and continuing through and including the Annual Meeting in 2009, the number of Reserved Shares will
be increased automatically by the least of (i) three quarters of one percent (0.75%) of the total number of shares of Common
Stock outstanding on such date, (ii) sixty thousand (60,000) shares, or (iii) a number of shares determined by the Board prior
to such date, which number shall be less than (i) and (ii) above.

 

(b)Reversion
of Shares to the Share Reserve. If any Option shall for any reason expire or otherwise terminate, in whole or in part, without
having been exercised in full, the shares of Common Stock not acquired under such Option shall revert to and again become available
for issuance under the Plan.

 

(c)Source of
Shares. The shares of Common Stock subject to the Plan may be unissued shares or reacquired shares, bought on the market or
otherwise.

 

5.Eligibility.

 

The Options as set
forth in Section 6 of the Plan automatically shall be granted under the Plan to all Non-Employee Directors.

 

6.Non-Discretionary Grants.

 

(a)[INTENTIONALLY
DELETED]

 

(b)Annual Grants.
Without any further action of the Board, a Non-Employee Director shall be granted an Annual Grant as follows:

 

(i)On the
day following each Annual Meeting commencing with the Annual Meeting in 2001 and continuing through and including the Annual Meeting
in 2011, each person who is then a Non-Employee Director automatically shall be granted an Annual Grant to purchase five thousand
(5,000) shares of Common Stock on the terms and conditions set forth herein.

 

In the event a Non-Employee Director begins
service on a date other than the date of the Annual Meeting, such Director shall be granted the pro rata amount of shares representing
the number of full calendar months of service remaining until the one year anniversary of the previous Annual Meeting.

 

    	4

    	 

    
 

 

(ii)On the
first Trading Day following each Annual Meeting commencing with the Annual Meeting in 2012, each person who is then a Non-Employee
Director automatically shall be granted an Annual Grant to purchase, on the terms and conditions set forth herein, the number of
shares of Common Stock equal to: (x) $65,000, divided by (y) 32% of the Average Fair Market Value of a share of Common Stock.

 

In the event a Non-Employee
Director begins service on a date other than the date of the Annual Meeting, on the first Trading Day following the commencement
of such service, such Director shall be granted an Annual Grant to purchase, on the terms and conditions set forth herein, the
number of shares of Common Stock equal to: (x) $65,000, divided by (y) 32% of the Average Fair Market Value of a share of
Common Stock; pro-rated for the number of full calendar months of service remaining until the one year anniversary of the previous
Annual Meeting.

 

For purposes of this
Section 6(b)(ii), “Trading Day” means a day on which the Applicable Market (as defined in Section 2(n)(i)) is open
for the buying and selling of securities.

 

For purposes of this
Section 6(b)(ii), “Average Fair Market Value” means:

 

(1)If the
Common Stock is listed on any established stock exchange or traded on any Nasdaq market, the Average Fair Market Value of a share
of Common Stock shall be the average of the Fair Market Value on each Trading Day during the thirty (30) calendar days preceding
the applicable grant date.

 

(2)If the
Common Stock is not listed on any established stock exchange or traded on any Nasdaq market, the Average Fair Market Value of a
share of Common Stock shall be determined in good faith by the Board.

 

7.Option Provisions.

 

Each Option shall be
in such form and shall contain such terms and conditions as required by the Plan. Each Option shall contain such additional terms
and conditions, not inconsistent with the Plan, as the Board shall deem appropriate. Each Option shall include (through incorporation
of provisions hereof by reference in the Option or otherwise) the substance of each of the following provisions:

 

(a)Term.
No Option shall be exercisable after the expiration of ten (10) years from the date it was granted.

 

(b)Exercise
Price. The exercise price of each Option shall be one hundred percent (100%) of the Fair Market Value of the stock subject
to the Option on the date the Option is granted. Notwithstanding the foregoing, an Option may be granted with an exercise price
lower than that set forth in the preceding sentence if such Option is granted pursuant to an assumption or substitution for another
option in a manner satisfying the provisions of Section 424(a) of the Code.

 

    	5

    	 

    
 

 

(c)Consideration.
The purchase price of stock acquired pursuant to an Option may be paid, to the extent permitted by applicable statutes and regulations,
in any combination of the following methods:

 

(i)By cash
or check.

 

(ii)Provided
that at the time of exercise the Common Stock is publicly traded and quoted regularly in The Wall Street Journal, by delivery
of already-owned shares of Common Stock either that the Optionholder has held for the period required to avoid a charge to the
Company’s reported earnings (generally six months) or that the Optionholder did not acquire, directly or indirectly from
the Company, that are owned free and clear of any liens, claims, encumbrances or security interests, and that are valued at Fair
Market Value on the date of exercise. “Delivery” for these purposes shall include delivery to the Company of the Optionholder’s
attestation of ownership of such shares of Common Stock in a form approved by the Company. Notwithstanding the foregoing, the Optionholder
may not exercise the Option by tender to the Company of Common Stock to the extent such tender would violate the provisions of
any law, regulation or agreement restricting the redemption of the Company’s stock.

 

(iii)Provided
that at the time of exercise the Common Stock is publicly traded and quoted regularly in The Wall Street Journal, pursuant
to a program developed under Regulation T as promulgated by the Federal Reserve Board that, prior to the issuance of Common Stock,
results in either the receipt of cash (or check) by the Company or the receipt of irrevocable instructions to pay the aggregate
exercise price to the Company from the sales proceeds.

 

(d)Transferability.
An Option is transferable by will or by the laws of descent and distribution. An Option also is transferable (i) by instrument
to an inter vivos or testamentary trust, in a form accepted by the Company, in which the Option is to be passed to beneficiaries
upon the death of the trustor (settlor) and (ii) by gift, in a form accepted by the Company, to a member of the “immediate
family” of the Optionholder as that term is defined in 17 C.F.R. 240.16a-1(e). An Option shall be exercisable during the
lifetime of the Optionholder only by the Optionholder and a permitted transferee as provided herein. However, the Optionholder
may, by delivering written notice to the Company, in a form satisfactory to the Company, designate a third party who, in the event
of the death of the Optionholder, shall thereafter be entitled to exercise the Option.

 

(e)Exercise
Schedule. The Option shall be exercisable as the shares of Common Stock subject to the Option vest. 

 

(f)Vesting Schedule.

 

(i)With respect
to Annual Grants granted on or prior to the Annual Meeting in 2012,  100% of the shares subject to the Annual Grant shall
vest on the one year anniversary of the previous Annual Meeting; provided, however, that if the Non-Employee Director is
not in Continuous Service between the date of grant and such one year anniversary, then the number of shares that shall vest as
of the Non-Employee Director's termination of Continuous Service will represent the pro rata amount for each full calendar month
such Non-Employee Director was in Continuous Service from the date of grant to such one year anniversary.

 

    	6

    	 

    
 

 

(ii)With respect
to Annual Grants granted following the Annual Meeting in 2012, 100% of the shares subject to the Annual Grant shall vest on the
earlier of (x) the one year anniversary of the previous Annual Meeting and (y) if the next Annual Meeting is held within thirty
(30) days of the one year anniversary of the previous Annual Meeting, the date of such next Annual Meeting; provided, however,
that if the Non-Employee Director is not in Continuous Service between the date of grant and such vesting date, then the number
of shares that shall vest as of the Non-Employee Director's termination of Continuous Service will represent the pro rata amount
for each full calendar month such Non-Employee Director was in Continuous Service from the date of grant to such one year anniversary.

 

(g)Termination
of Continuous Service. In the event an Optionholder’s Continuous Service terminates (other than upon the Optionholder’s
death or Disability), the Optionholder may exercise his or her Option (to the extent that the Optionholder was entitled to exercise
it as of the date of termination) but only within such period of time ending on the earlier of (i) the date three (3) months following
the termination of the Optionholder’s Continuous Service, or (ii) the expiration of the term of the Option as set forth in
the Option Agreement. If, after termination, the Optionholder does not exercise his or her Option within the time specified in
the Option Agreement, the Option shall terminate.

 

(h)Extension
of Termination Date. If the exercise of the Option following the termination of the Optionholder’s Continuous Service
(other than upon the Optionholder’s death or Disability) would be prohibited at any time solely because the issuance of shares
would violate the registration requirements under the Securities Act, then the Option shall terminate on the earlier of (i) the
expiration of the term of the Option set forth in subsection 7(a) or (ii) the expiration of a period of three (3) months after
the termination of the Optionholder’s Continuous Service during which the exercise of the Option would not be in violation
of such registration requirements.

 

(i)Disability
of Optionholder. In the event an Optionholder’s Continuous Service terminates as a result of the Optionholder’s
Disability, the Optionholder may exercise his or her Option (to the extent that the Optionholder was entitled to exercise it as
of the date of termination), but only within such period of time ending on the earlier of (i) the date twelve (12) months following
such termination or (ii) the expiration of the term of the Option as set forth in the Option Agreement. If, after termination,
the Optionholder does not exercise his or her Option within the time specified herein, the Option shall terminate.

 

(j)Death of
Optionholder. In the event (i) an Optionholder’s Continuous Service terminates as a result of the Optionholder’s
death or (ii) the Optionholder dies within the three-month period after the termination of the Optionholder’s Continuous
Service for a reason other than death, then the Option may be exercised (to the extent the Optionholder was entitled to exercise
the Option as of the date of death) by the Optionholder’s estate, by a person who acquired the right to exercise the Option
by bequest or inheritance or by a person designated to exercise the Option upon the Optionholder’s death, but only within
the period ending on the earlier of (1) the date eighteen (18) months following the date of death or (2) the expiration of the
term of such Option as set forth in the Option Agreement. If, after death, the Option is not exercised within the time specified
herein, the Option shall terminate.

 

    	7

    	 

    
 

 

8.Covenants of the Company.

 

(a)Availability
of Shares. During the terms of the Options, the Company shall keep available at all times the number of shares of Common Stock
required to satisfy such Options.

 

(b)Securities
Law Compliance. The Company shall seek to obtain from each regulatory commission or agency having jurisdiction over the Plan
such authority as may be required to grant Options and to issue and sell shares of Common Stock upon exercise of the Options; provided,
however, that this undertaking shall not require the Company to register under the Securities Act the Plan, any Option or any stock
issued or issuable pursuant to any such Option. If, after reasonable efforts, the Company is unable to obtain from any such regulatory
commission or agency the authority which counsel for the Company deems necessary for the lawful issuance and sale of stock under
the Plan, the Company shall be relieved from any liability for failure to issue and sell stock upon exercise of such Options unless
and until such authority is obtained.

 

9.Use of Proceeds from Stock.

 

Proceeds from the sale
of stock pursuant to Options shall constitute general funds of the Company.

 

10.Miscellaneous.

 

(a)Stockholder
Rights. No Optionholder shall be deemed to be the holder of, or to have any of the rights of a holder with respect to, any
shares subject to such Option unless and until such Optionholder has satisfied all requirements for exercise of the Option pursuant
to its terms.

 

(b)No Service
Rights. Nothing in the Plan or any instrument executed or Option granted pursuant thereto shall confer upon any Optionholder
any right to continue to serve the Company as a Non-Employee Director or shall affect the right of the Company or an Affiliate
to terminate (i) the employment of an Employee with or without notice and with or without cause, (ii) the service of a Consultant
pursuant to the terms of such Consultant’s agreement with the Company or an Affiliate or (iii) the service of a Director
pursuant to the Bylaws of the Company or an Affiliate, and any applicable provisions of the corporate law of the state in which
the Company or the Affiliate is incorporated, as the case may be.

 

(c)Investment
Assurances. The Company may require an Optionholder, as a condition of exercising or acquiring stock under any Option, (i)
to give written assurances satisfactory to the Company as to the Optionholder’s knowledge and experience in financial and
business matters and/or to employ a purchaser representative reasonably satisfactory to the Company who is knowledgeable and experienced
in financial and business matters and that he or she is capable of evaluating, alone or together with the purchaser representative,
the merits and risks of exercising the Option; and (ii) to give written assurances satisfactory to the Company stating that the
Optionholder is acquiring the stock subject to the Option for the Optionholder’s own account and not with any present intention
of selling or otherwise distributing the stock. The foregoing requirements, and any assurances given pursuant to such requirements,
shall be inoperative if (1) the issuance of the shares upon the exercise or acquisition of stock under the Option has been registered
under a then currently effective registration statement under the Securities Act or (2) as to any particular requirement, a determination
is made by counsel for the Company that such requirement need not be met in the circumstances under the then applicable securities
laws. The Company may, upon advice of counsel to the Company, place legends on stock certificates issued under the Plan as such
counsel deems necessary or appropriate in order to comply with applicable securities laws, including, but not limited to, legends
restricting the transfer of the stock.

 

    	8

    	 

    
 

 

(d)Withholding
Obligations. The Optionholder may satisfy any federal, state or local tax withholding obligation relating to the exercise or
acquisition of stock under an Option by any of the following means (in addition to the Company’s right to withhold from any
compensation paid to the Optionholder by the Company) or by a combination of such means: (i) tendering a cash payment; (ii) authorizing
the Company to withhold shares from the shares of the Common Stock otherwise issuable to the Optionholder as a result of the exercise
or acquisition of stock under the Option, provided, however, that no shares of Common Stock are withheld with a value exceeding
the minimum amount of tax required to be withheld by law; or (iii) delivering to the Company owned and unencumbered shares of the
Common Stock.

 

11.Adjustments upon Changes in Stock.

 

(a)Capitalization
Adjustments. If any change is made in the stock subject to the Plan, or subject to any Option, without the receipt of consideration
by the Company (through merger, consolidation, reorganization, recapitalization, reincorporation, stock dividend, dividend in property
other than cash, stock split, liquidating dividend, combination of shares, exchange of shares, change in corporate structure or
other transaction not involving the receipt of consideration by the Company), the Plan will be appropriately adjusted in the class(es)
and maximum number of securities subject both to the Plan pursuant to subsection 4(a) and to the nondiscretionary Options specified
in Section 6, and the outstanding Options will be appropriately adjusted in the class(es) and number of securities and price per
share of stock subject to such outstanding Options. The Board shall make such adjustments, and its determination shall be final,
binding and conclusive. (The conversion of any convertible securities of the Company shall not be treated as a transaction “without
receipt of consideration” by the Company.)

 

(b)Dissolution
or Liquidation. In the event of a dissolution or liquidation of the Company, then all outstanding Options shall terminate immediately
prior to such event.

 

(c)Corporate
Transaction. In the event of (i) a sale, lease or other disposition of all or substantially all of the securities or assets
of the Company, (ii) a merger or consolidation in which the Company is not the surviving corporation or (iii) a reverse merger
in which the Company is the surviving corporation but the shares of Common Stock outstanding immediately preceding the merger are
converted by virtue of the merger into other property, whether in the form of securities, cash or otherwise (each, a “Corporate
Transaction”), then with respect to Options held by Optionholders whose Continuous Service has not terminated, the vesting
of such Options (and the time during which such Options may be exercised) shall be accelerated in full, and the Options shall terminate
if not exercised at or prior to the Corporate Transaction. With respect to any other Options outstanding under the Plan, such Options
shall terminate if not exercised prior to the Corporate Transaction.

 

    	9

    	 

    
 

 

12.Amendment of the Plan and Options.

 

(a)Amendment
of Plan. The Board at any time, and from time to time, may amend the Plan. However, except as provided in Section 11 relating
to adjustments upon changes in stock, no amendment shall be effective unless approved by the shareholders of the Company to the
extent stockholder approval is necessary to satisfy the requirements of Rule 16b-3 or any Nasdaq or securities exchange listing
requirements.

 

(b)Stockholder
Approval. The Board may, in its sole discretion, submit any other amendment to the Plan for stockholder approval.

 

(c)No Impairment
of Rights. Rights under any Option granted before amendment of the Plan shall not be impaired by any amendment of the Plan
unless (i) the Company requests the consent of the Optionholder and (ii) the Optionholder consents in writing.

 

(d)Amendment
of Options. The Board at any time, and from time to time, may amend the terms of any one or more Options; provided, however,
that the rights under any Option shall not be impaired by any such amendment unless (i) the Company requests the consent of the
Optionholder and (ii) the Optionholder consents in writing.

 

13.Termination or Suspension of
the Plan.

 

(a)Plan Term.
The Board may suspend or terminate the Plan at any time. No Options may be granted under the Plan while the Plan is suspended or
after it is terminated.

 

(b)No Impairment
of Rights. Suspension or termination of the Plan shall not impair rights and obligations under any Option granted while the
Plan is in effect except with the written consent of the Optionholder.

 

14.Effective Date of Plan.

 

The Plan became effective
on the IPO Date and the Plan was approved by the shareholders of the Company on November 17, 2000. The amended and restated Plan
shall become effective as the date approved by the Board.

 

15.Choice of Law.

 

All questions concerning
the construction, validity and interpretation of this Plan shall be governed by the law of the State of Washington, without regard
to such state’s conflict of laws rules.

 

    	10EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

Exclusive
Channel Collaboration Agreement

 

This
Exclusive Channel Collaboration Agreement (the “Agreement”) is made and entered into effective as
of August 6, 2012 (the “Effective Date”) by and between Intrexon Corporation,
a Virginia corporation with offices at 20358 Seneca Meadows Parkway, Germantown, MD 20876 (“Intrexon”), and
Synthetic Biologics, Inc., a Nevada corporation having its principal place
of business at 617 Detroit Street, Suite 100, Ann Arbor, MI 48104 (“Synthetic”). Intrexon and Synthetic may
be referred to herein individually as a “Party”, and collectively as the “Parties.”

 

Recitals

 

Whereas,
Intrexon has expertise in and owns or controls proprietary technology relating to the identification, design and production
of human antibodies and DNA vectors; and

 

Whereas,
Synthetic now desires to become Intrexon’s exclusive channel collaborator with respect to such technology for the purpose
of developing the Anti-Infectives Program (as defined herein), and Intrexon is willing to appoint Synthetic as a channel collaborator
in the Field (as defined herein, and subject to amendments to the definition as permitted herein) under the terms and conditions
of this Agreement.

 

Now
Therefore, in consideration of the foregoing and the covenants and promises contained herein, the Parties agree as follows:

 

ARTICLE
1

Definitions

 

As used in this Agreement,
the following capitalized terms shall have the following meanings:

 

1.1                  
“Affiliate” means, with respect to a particular Party, any other person or entity that directly
or indirectly controls, is controlled by, or is in common control with such Party. As used in this Section 1.1, the term “controls”
(with correlative meanings for the terms “controlled by” and “under common control with”) means the ownership,
directly or indirectly, of more than fifty percent (50%) of the voting securities or other ownership interest of an entity, or
the possession, directly or indirectly, of the power to direct the management or policies of an entity, whether through the ownership
of voting securities, by contract, or otherwise. Notwithstanding the foregoing, any person, corporation, partnership, or other
entity that would be an Affiliate of a Party solely because it and such Party are under common control by Third Security or Randal
J. Kirk shall not be deemed to be an Affiliate of such Party solely by reason of such common control, with the caveat that, notwithstanding
the foregoing, any entity other than Synthetic affiliated with Third Security or Randal J. Kirk shall be deemed to be an Affiliate
of Intrexon solely for purposes of Article 9.

 

    	2

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

1.2                  
“Applicable Laws” has the meaning set forth in Section 8.2(d)(xii).

 

1.3                   
“Anti-Infectives Program” has the meaning set forth in Section 2.1(a).

 

1.4                  
“Authorizations” has the meaning set forth in Section 8.2(d)(xii).

 

1.5                  
“CC” has the meaning set forth in Section 2.2(b).

 

1.6                  
“Channel-Related Program IP” has the meaning set forth in Section 6.1(c).

 

1.7                  
“Claims” has the meaning set forth in Section 9.1.

 

1.8                  
“CMCC” has the meaning set forth in Section 2.2(b).

 

1.9                  
“Committees” has the meaning set forth in Section 2.2(a).

 

1.10              
“Commercialize” or “Commercialization” means any activities directed to
marketing, promoting, distributing, importing for sale, offering to sell and/or selling Synthetic Products.

 

1.11              
“Commercial Sale” means for a given product and country the sale for value of that product
by a Party (or, as the case may be, by an Affiliate or permitted sublicensee of a Party), to a Third Party after regulatory approval
(and any pricing or reimbursement approvals, if necessary) has been obtained for such product in such country.

 

1.12              
“Complementary In-Licensed Third Party IP” has the meaning set forth in Section 3.9(a).

 

1.13              
“Confidential Information” means each Party’s confidential Information, inventions, non-public
know-how or non-public data disclosed pursuant to this Agreement or any other confidentiality agreement between the Parties and
shall include, without limitation, manufacturing, technical, marketing, financial, personnel and other business information and
plans, whether in oral, written, graphic or electronic form.

 

1.14              
“Control” means, with respect to Information, a Patent or other intellectual property right, that
a Party owns or has a license from a Third Party to such right and has the ability to grant a license or sublicense as provided
for in this Agreement under such right without violating the terms of any agreement or other arrangement with any Third Party.

 

1.15              
“CRC” has the meaning set forth in Section 2.2(b).

 

1.16              
“Diligent Efforts” means, with respect to a Party’s obligation under this Agreement, the level
of efforts and resources reasonably required to diligently develop, manufacture, and/or Commercialize (as applicable) each Synthetic
Product in a sustained manner, consistent with the efforts and resources a similarly situated company working in the Field would
typically devote to a product of similar market potential, profit potential, strategic value and/or proprietary protection, based
on market conditions then prevailing. With respect to a particular task or obligation, Diligent Efforts requires that the applicable
Party promptly assign responsibility for such task and consistently make and implement decisions and allocate resources designed
to advance progress with respect to such task or obligation.

 

    	2

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

1.17              
“Equity Agreements” has the meaning set forth in Section 5.1.

 

1.18              
“Excess Product Liability Costs” has the meaning set forth in Section 9.3.

 

1.19              
“Executive Officer” means : (i) the Chief Executive Officer of the applicable Party, or (ii) another
senior executive officer of such Party who has been duly appointed by the Chief Executive Officer to act as the representative
of the Party to resolve, as the case may be, (a) a Committee dispute, provided that such appointed officer is not a member of the
applicable Committee and occupies a position senior to the positions occupied by the applicable Party’s members of the applicable
Committee, or (b) a dispute described in Section 11.1.

 

1.20              
“FDA” has the meaning set forth in Section 8.2(d)(xiii).

 

1.21              
“Field Infringement” has the meaning set forth in Section 6.3(b)

 

1.22              
“Field” means the exogenous production and use of human recombinant monoclonal antibodies, and mixes
thereof, for the treatment of the following eight (8) target toxins and/or diseases in humans (irespective of whether such requires
regulatory approval) : [*****]. The Field as defined in the previous sentence is subject to amendment according to the mechanisms
described in Sections 2.1(b), 2.1(c) and 2.1(d) of this Agreement. Unless context or usage for a particular reference herein to
Field dictates otherwise, each particular reference to Field in this Agreement should be interpreted as meaning the definition
of the Field that is in effect at the particular point in time that is relevant to that particular reference.

 

1.23              
“Fully Loaded Cost” means the direct cost of the applicable good, product or service plus indirect
charges and overheads reasonably allocable to the provision of such good, product or service in accordance with US GAAP. Subject
to the approval of a project and its associated budget by the JSC and the terms of Sections 4.6 and 4.7 (as appropriate), Intrexon
will bill for its internal direct costs incurred through the use of annualized standard full-time equivalents; such rate shall
be based upon the actual fully loaded costs of those personnel directly involved in the provision of such good, product or service.
Intrexon may, from time to time, adjust such full-time equivalent rate based on changes to its actual fully loaded costs and will
review the accuracy of its full-time equivalent rate at least quarterly. Intrexon shall provide Synthetic with reasonable documentation
indicating the basis for any direct and indirect charges, any allocable overhead, and any such adjustment in full-time equivalent
rate.

 

1.24              
 “In-Licensed Program IP” has the meaning set forth in Section
3.9(a).

 

    	3

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

1.25              
 “Information” means information, results and data of any type whatsoever, in any tangible or intangible
form whatsoever, including without limitation, databases, inventions, practices, methods, techniques, specifications, formulations,
formulae, knowledge, know-how, skill, experience, test data including pharmacological, biological, chemical, biochemical, toxicological
and clinical test data, analytical and quality control data, stability data, studies and procedures, and patent and other legal
information or descriptions.

 

1.26              
“Infringement” has the meaning set forth in Section 6.3(a).

 

1.27              
“Intrexon Channel Technology” means Intrexon’s current and future
technology directed towards the design, identification, and/or production of recombinant monoclonal antibodies, including
without limitation the technology embodied in the Intrexon Materials and the Intrexon IP, and specifically including without limitation
the following of Intrexon’s platform areas and capabilities: (1) UltraVector®, (2) mAbLogixTM
(3) DNA and RNA MOD engineering, (4) protein engineering, (5) transcription control chemistry, (6) genome engineering, (7) LEAPTM,
and (8) cell system engineering.

 

1.28              
“Intrexon Indemnitees” has the meaning set forth in Section 9.2.

 

1.29              
“Intrexon IP” means the Intrexon Patents and Intrexon Know-How.

 

1.30              
“Intrexon Know-How” means all Information (other than Intrexon Patents) that (a) is Controlled by
Intrexon as of the Effective Date or during the Term and (b) is reasonably required or useful for Synthetic
to conduct the Anti-Infectives Program. For the avoidance of doubt, the Intrexon Know-How shall include any Information (other
than Intrexon Patents) in the Channel-Related Program IP.

 

1.31              
“Intrexon Materials” means the genetic code and associated amino acids and gene constructs used alone
or in combination and such other proprietary reagents including but not limited to plasmid vectors, virus stocks, cells and cell
lines, antibodies, and ligand-related chemistry, in each case that are reasonably required or provided to Synthetic to conduct
the Anti-Infectives Program.

 

1.32              
“Intrexon Patents” means all Patents that (a) are Controlled by Intrexon as of the Effective Date
or during the Term; and (b) are reasonably required or useful for Synthetic to conduct the Anti-Infectives Program. For the avoidance
of doubt, the Intrexon Patents shall include any Patent in the Channel-Related Program IP.

 

1.33              
“Intrexon Trademarks” means those trademarks related to the Intrexon Channel Technology that are
established from time to time by Intrexon for use across its channel partnerships or collaborations.

 

1.34              
“Inventions” has the meaning set forth in Section 6.1(b).

 

1.35              
“IPC” has the meaning set forth in Section 2.2(b).

 

    	4

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

1.36              
“JSC” has the meaning set forth in Section 2.2(b).

 

1.37              
“Losses” has the meaning set forth in Section 9.1.

 

1.38              
“Net Sales” means, with respect to any Synthetic Product, the net sales of such Synthetic Product
by Synthetic or an Affiliate of Synthetic (including without limitation net sales of Synthetic Product to a non-Affiliate sublicensee
but not including net sales by such non-Affiliate sublicensee), as determined in accordance with US GAAP as the gross amount invoiced
on account of sales of Synthetic Product less the usual and customary discounts as determined in accordance with US GAAP. In the
case of any sale for value, such as barter or counter-trade other than in an arm’s length transaction exclusively for cash,
Net Sales shall be deemed to be the net sales at which substantially similar quantities of the product are sold for cash in an
arm’s length transaction in the relevant country. If Synthetic Product is sold to any third party together with other products
or services, the price of such product, solely for purposes of the calculation of Net Sales, shall be deemed to be no less than
the price at which such product would be sold in a similar transaction to a third party not also purchasing the other products
or services.

 

1.39              
“Patents” means (a) all patents and patent applications (including provisional applications), (b)
any substitutions, divisions, continuations, continuations-in-part, reissues, renewals, registrations, requests for continued examination,
confirmations, re-examinations, extensions, supplementary protection certificates and the like of the foregoing, and (c) any foreign
or international equivalents of any of the foregoing.

 

1.40              
“Primary Program Targets” has the meaning as set forth in Section 2.1(b).

 

1.41              
“Product-Specific Program Patent” means any issued Intrexon Patent where all the claims are directed
to Inventions that relate solely and specifically to Synthetic Products. In the event of a disagreement between the Parties as
to whether a particular Intrexon Patent is or is not a Product-Specific Program Patent, the Parties shall seek to resolve the issue
through discussions at the IPC, provided that if the Parties are unable to resolve the disagreement, the issue shall be submitted
to arbitration pursuant to Section 11.2. Any Intrexon Patent that is subject to such a dispute shall be deemed not to be a Product-Specific
Program Patent unless and until (a) Intrexon agrees in writing that such Patent is a Product-Specific Program Patent or (b) an
arbitrator or arbitration panel determines, pursuant to Article 11, that such Intrexon Patent is a Product-Specific Program Patent.

 

1.42              
“Proposed Terms” has the meaning set forth in Section 11.2.

 

1.43              
“Prosecuting Party” has the meaning set forth in Section 6.2(c).

 

1.44              
“Recovery” has the meaning set forth in Section 6.3(f).

 

1.45              
“Retained Product” has the meaning set forth in Section 10.4(a).

 

1.46              
“Reverted Product” has the meaning set forth in Section 10.4(c).

 

    	5

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

1.47              
“SEC” means the United States Securities and Exchange Commission.

 

1.48              
“Sublicensing Revenue” means any cash consideration, or the cash equivalent value of non-cash consideration,
regardless of whether in the form of upfront payments, milestones, or royalties, actually received by Synthetic or its Affiliate
from a Third Party in consideration for a grant of a sublicense under the Intrexon IP or any rights to develop or commercialize
Synthetic Products, but excluding: (a) any amounts paid as bona fide reimbursement for research and development costs to the extent
incurred following such grant; (b) bona fide loans or any payments in consideration for a grant of equity of Synthetic to the extent
that such consideration is equal to or less than fair market value (i.e. any amounts in excess of fair market value shall be Sublicensing
Revenue); and (d) amounts received from sublicensees in respect of any Synthetic Product sales that are included in Net Sales.
 

 

1.49              
“Superior Therapy” means a therapy in the Field that, based on the data then available, (a) demonstrably
appears to offer either superior efficacy or safety or significantly lower cost of therapy, as compared with both (i) those therapies
that are marketed (either by Synthetic or others) at such time for the indication and (ii) those therapies that are being actively
developed by Synthetic for such indication; (b) demonstrably appears to represent a substantial improvement over such existing
therapies; and (c) has intellectual property protection and a regulatory approval pathway that, in each case, would not present
a significant barrier to commercial development.

 

1.50              
“Supplemental In-Licensed Third Party IP” has the meaning set forth in Section 3.8(a).

 

1.51              
“Support Memorandum” has the meaning set forth in Section 11.2.

 

1.52              
“Synthetic Indemnitees” has the meaning set forth in Section 9.1.

 

1.53              
“Synthetic Product” means any product in the Field that is created, produced, developed, or identified
in whole or in part, directly or indirectly, by or on behalf of Synthetic during the Term through use or practice of Intrexon Channel
Technology, Intrexon IP, or the Intrexon Materials.

 

1.54              
“Synthetic Program Patent” has the meaning set forth in Section 6.2(b).

 

1.55              
“Synthetic Termination IP” means all Patents or other intellectual property that Synthetic or any
of its Affiliates Controls as of the Effective Date or during the Term that cover, or is otherwise necessary or useful for, the
development, manufacture or commercialization of a Reverted Product or necessary or useful for Intrexon to operate in the Field.

 

1.56              
“Term” has the meaning set forth in Section 10.1.

 

1.57              
“Territory” means the entire world.

 

    	6

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

1.58              
“Third Party” means any individual or entity other than the Parties or their respective Affiliates.

 

1.59              
“Third Security” means Third Security, LLC.

 

1.60              
 “US GAAP” means generally accepted accounting principles in the United States.

 

ARTICLE
2

Scope of Channel Collaboration; Management

 

2.1                  
Scope.

 

(a)              
Generally. The general purpose of the channel collaboration described in this Agreement will be to use
the Intrexon Channel Technology to research, develop and commercialize products for use in the Field (collectively, the “Anti-Infectives
Program”). As provided below, the JSC shall establish, monitor, and govern projects for the Anti-Infectives Program.
Either Party may propose potential projects in the Field for review and consideration by the JSC.

 

(b)              
Initial Project for Immediate Commencement.The Parties as of the Effective Date have identified three
specific targets in the Field as being desirable projects for immediate development under the Anti-Infectives Program (the “Primary
Program Targets”), and the JSC will be directed upon its creation to produce, and thereafter initiate performance of,
an initial research project for the production of Synthetic Products for each of the Primary Program Targets. The Primary Program
Targets are : [*****]. Synthetic will review data derived from these research projects for the Primary Program Targets via the
JSC and will use such to consider the scientific and commercial viability of the Primary Program Targets. The JSC, consistent
with its authority herein and subject to Synthetic’s agreement to reimburse Intrexon for expenses relating thereto in accord
with Section 4.7 below, may also authorize additional research projects for any of the five (5) other targets in the Field that
are not Primary Program Targets. Such additional research projects may be authorized by the JSC prior to Synthetic making its
election in accord with Section 2.1(c) below. Further, at any time prior to the two-year anniversary of the Effective Date and
prior to the election by Synthetic under Section 2.1(c), Synthetic at its sole discretion may suspend the initial research project
for one or more of the Primary Program Targets, and swap for such, on a one-for-one basis, any of the five (5) other targets in
the Field that are not Primary Program Targets. In the event that Synthetic swaps out a Primary Program Target as set forth in
the previous sentence, or in the event that Synthetic otherwise suspends or terminates the initial research project for a Primary
Program Target prior to making its election under Section 2.1(c), the definition of Field under Section 1.21 above will be automatically
amended such that the suspended, terminated, or swapped-out Primary Program Target will be removed automatically, immediately
and irrevocably from the Field, and thereby all obligations and rights

 

    	7

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

of the Parties as set forth herein which are defined at
least in part by or in conjunction with the Field will likewise be immediately amended as such from that time forward. In the
event that Synthetic swaps out a Primary Program Target as set forth in the previous sentence, the Primary Program Targets will
be automatically amended such that any swapped-out Primary Program Target is removed and replaced with the other target in the
Field chosen to be swapped-in by Synthetic, and thereby all obligations and rights of the Parties as set forth herein which are
defined at least in part by or in conjunction with the Primary Program Targets will likewise be immediately amended as such from
that time forward. Any Synthetic Products corresponding to these suspended, terminated, or swapped-out Primary Program Targets
will be treated as Reverted Products in accord with Section 10.4. 

 

(c)               
Field Election. On or before the two-year anniversary of the Effective Date, Synthetic must notify Intrexon
in writing of Synthetic’s final and binding election, which election identifies up to three (3) target toxins or diseases
in the Field (as the Field is defined at the point in time of the notification, taking into account any amendments to its definition
caused by operation of Section 2.1(b)). Such election must reference this Section 2.1(c), will be effective immediately upon receipt
by Intrexon, and will cause the definition of Field under this agreement to be amended immediately and permanently such that the
Field from that time forward shall include only those three (3) elected toxins or diseases (and not any of the toxins or diseases
not elected). All rights and obligations of the Parties under this Agreement within and without the Field will be permanently altered
accordingly from the date of receipt of that election forward for the remaining Term. For any of the target toxins or diseases
in the Field that are not elected by Synthetic under this Section 2.1(c), Synthetic (i) shall immediately cease, and shall cause
its Affiliates and, if applicable, (sub)licensees to immediately cease, all development and Commercialization of Synthetic Products
pertaining thereto; (ii), shall not use or practice, nor shall it cause or permit any of its Affiliates or, if applicable, (sub)licensees
to use or practice, directly or indirectly, any Intrexon IP with respect to such; and (iii) shall return to Intrexon, or destroy
all copies thereto at Intrexon’s option, all data and materials relating to such not-elected indications. Any Synthetic Products
corresponding to these not-elected indications will be treated as Reverted Products in accord with Section 10.4.

 

(d)              
Effect of No Election. In the event that Synthetic does not communicate an election to Intrexon under
Section 2.1(c) on or before the two-year anniversary of the Effective Date, the definition of Field will be amended automatically,
immediately and permanently such that on the day after the two-year anniversary of the Effective Date the Field shall include only
the Primary Program Targets and not any of the other target toxins or diseases that are not Primary Program Targets. All rights
and obligations of the Parties under this Agreement which are defined at least in part by or in conjunction with the Field will
thereby be permanently altered accordingly for the remaining Term from that time forward.

 

(e)               
Option to Expand Field Election. Synthetic, at its sole option, may expand its election rights under Section
2.1(c) to enable it to elect up to five (5) additional indications from the list of items (a) through (h) in Section 1.21 if :
(i) prior to or concurrent with making an election under Section 2.1(c) Synthetic notifies Intrexon in writing of its intent to
expand its election rights in accord with this Section 2.1(e), and (ii) Synthetic remits a payment, in cash or equity at Synthetic’s
sole discretion, to Intrexon

 

    	8

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

of two million dollars ($2M) for each target in excess of three (3) that it desires to elect under
Section 2.1(c). Any payment under this section made by Synthetic in equity must be made in compliance with the terms of the Equity
Agreements. Any expansion of Synthetic’s election rights under Section 2.1(c) hereunder shall not be effective until the
appropriate payment required under this Section 2.1(e) is received by Intrexon, and cannot be used to enable Synthetic to elect
any targets that were already permanently removed from the Field under Section 2.1(b). Upon successful execution of the option
to expand under this Section 2.1(e), all rights and obligations of the Parties under this Agreement within and without the Field
will be permanently altered accordingly from the date of receipt of that option forward for the remaining Term.

 

2.2                  
Committees.

 

(a)              
Generally. The Parties desire to establish several committees (collectively, “Committees”)
to oversee the Anti-Infectives Program and to facilitate communications between the Parties with respect thereto. Each of such
Committees shall have the responsibilities and authority allocated to it in this Article 2. Each of the Committees shall have the
obligation to exercise its authority consistent with the respective purpose for such Committee as stated herein and any such decisions
shall be made in good faith.

 

(b)              
Formation and Purpose. Promptly following the Effective Date, the Parties shall confer and then create
the Committees listed in the chart below, each of which shall have the purpose indicated in the chart. To the extent that after
conferring both Parties agree that a given Committee need not be created until a later date, the Parties may agree to defer the
creation of the Committee until one Party informs the other Party of its then desire to create the so-deferred Committee, at which
point the Parties will thereafter promptly create the so-deferred Committee and schedule a meeting of such Committee within one
(1) month.

 

	Committee	Purpose
	Joint Steering Committee (“JSC”)	
        Establish projects for the Anti-Infectives Program and establish
        the priorities, as well as approve budgets for such projects. Approve all subcommittee projects and plans. The JSC shall establish
        budgets not less than on a quarterly basis.

         

         

	Chemistry, Manufacturing and Controls Committee (“CMCC”)	Establish project plans and review and approve activities and budgets for chemistry, manufacturing, and controls under the Anti-Infectives Program.

 

    	9

    	 

    
 EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

	Committee	Purpose

	Clinical/Regulatory Committee (“CRC”)	Review and approve all research and development plans, clinical projects and publications, and regulatory filings and correspondence under the Anti-Infectives Program; review and approve itemized budgets with respect to the foregoing.
	Commercialization Committee (“CC”)	Establish project plans and review and approve activities and budgets for commercialization activities under the Anti-Infectives Program.
	Intellectual Property Committee (“IPC”)	Evaluate intellectual property issues in connection with the Anti-Infectives Program; review and approve itemized budgets with respect to the foregoing.

 

2.3                  
General Committee Membership and Procedure.

 

(a)              
Membership. For each Committee, each Party shall designate an equal number of representatives (not to
exceed four (4) for each Party) with appropriate expertise to serve as members of such Committee. For the JSC the representatives
must all be employees of such Party or an Affiliate of such Party, and for Committees other than the JSC the representatives must
all be employees of such Party or an Affiliate of such Party with the caveat that each Party may designate for each such other
Committee up to one (1) representative who is not an employee if : (i) such non-employee representative agrees in writing to be
bound to the terms of this Agreement for the treatment and ownership of Confidential Information and Inventions of the Parties,
and (ii) the other Party consents to the designation of such non-employee representative, which consent shall not be unreasonably
withheld. Each representative as qualified above may serve on more than one Committee as appropriate in view of the individual’s
expertise. Each Party may replace its Committee representatives at any time upon written notice to the other Party. Each Committee
shall have a chairperson; the chairperson of each committee shall serve for a two-year term and the right to designate which representative
to the Committee will act as chairperson shall alternate between the Parties, with Synthetic selecting the chairperson first for
the JSC, CRC and CC, and Intrexon selecting the chairperson first for the CMCC and IPC. The chairperson of each Committee shall
be responsible for calling meetings, preparing and circulating an agenda in advance of each meeting of such Committee, and preparing
and issuing minutes of each meeting within fifteen (15) days thereafter.

 

    	10

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

(b)              
Meetings. Each Committee shall hold meetings at such times as it elects to do so, but in no event shall
such meetings be held less frequently than once every six (6) months, with the caveat that both Parties may agree to suspend activities
of a given Committee other than the JSC until such time as one Party informs the other Party of its then desire to reactivate the
so-suspended Committee, at which point the Parties will thereafter schedule and hold the next meeting for the reactivated Committee
within one (1) month. Meetings of any Committee may be held in person or by means of telecommunication (telephone, video, or web
conferences). To the extent that a Committee holds any meetings in person, the Parties will alternate in designating the location
for such in-person meetings, with Synthetic selecting the first meeting location for each Committee. A reasonable number of additional
representatives of a Party may attend meetings of a Committee in a non-voting capacity. Each Party shall be responsible for all
of its own expenses of participating in any Committee excepting that an Intrexon employee or agent serving on a Committee shall
not prevent Intrexon from recouping the Fully Loaded Costs otherwise derived from the labor of that employee or agent in the course
of providing manufacturing or support services as set forth in Sections 4.6 and 4.7 below.

 

(c)               
Meeting Agendas. Each Party will disclose to the other proposed agenda items along with appropriate information
at least three (3) business days in advance of each meeting of the applicable Committee; provided, that a Party may provide its
agenda items to the other Party within a lesser period of time in advance of the meeting, or may propose that there not be a specific
agenda for a particular meeting, so long as such other Party consents to such later addition of such agenda items or the absence
of a specific agenda for such Committee meeting..

 

(d)              
Limitations of Committee Powers. Each Committee shall have only such powers as are specifically delegated
to it hereunder or from time to time as agreed to in writing by the mutual consent of the Parties and shall not be a substitute
for the rights of the Parties. Without limiting the generality of the foregoing, no Committee shall have any power to amend this
Agreement. Any amendment to the terms and conditions of this Agreement shall be implemented pursuant to Section 12.7 below.

 

2.4                  
Committee Decision-Making. If a Committee is unable to reach unanimous consent on a particular matter
within thirty (30) days of its initial consideration of such matter, then either Party may provide written notice of such dispute
to the Executive Officer of the other Party. The Executive Officers of each of the Parties will meet at least once in person or
by means of telecommunication (telephone, video, or web conferences) to discuss the dispute and use their good faith efforts to
resolve the dispute within thirty (30) days after submission of such dispute to the Executive Officers. If any such dispute is
not resolved by the Executive Officers within thirty (30) days after submission of such dispute to such officers, then the Executive
Officer of the Party specified in the applicable subsection below shall have the authority to finally resolve such dispute acting
in good faith.

 

(a)              
Casting Vote at JSC. If a dispute at the JSC is not resolved pursuant to Section 2.4 above, then the Executive
Officer of Synthetic shall have the authority to finally resolve such dispute.

 

    	11

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

(b)              
Casting Vote at CMCC. If a dispute at the CMCC is not resolved pursuant to Section 2.4 above, then (i)
in the case of any disputes relating to the Intrexon Materials or controls regarding the dissemination of Intrexon IP or Intrexon
Materials, the Executive Officer of Intrexon shall have the authority to finally resolve such dispute; and (ii) in the case of
any other disputes, including the manufacture of a Synthetic Product active pharmaceutical ingredient, the Executive Officer of
Synthetic shall have the authority to finally resolve such dispute.

 

(c)               
Casting Vote at CRC. If a dispute at the CRC is not resolved pursuant to Section 2.4 above, then the Executive
Officer of Synthetic shall have the authority to finally resolve such dispute.

 

(d)              
Casting Vote at CC. If a dispute at the CC is not resolved pursuant to Section 2.4 above, then the Executive
Officer of Synthetic shall have the authority to finally resolve such dispute.

 

(e)               
Casting Vote at IPC. If a dispute at the IPC is not resolved pursuant to Section 2.4 above, then the Executive
Officer of Intrexon shall have the authority to finally resolve such dispute, provided that such authority shall be shared by the
Parties with respect to Product-Specific Program Patents (i.e., neither Party shall have the casting vote on such matters, and
any such disputes shall be resolved pursuant to Article 11).

 

(f)               
Other Committees. If any additional Committee other than those set forth in Section 2.2(b) is formed,
then the Parties shall, at the time of such formation, agree on which Party shall have the authority to finally resolve a dispute
that is not resolved pursuant to Section 2.4 above.

 

(g)              
Restrictions. Neither Party shall exercise its right to finally resolve a dispute at a Committee in accordance
with this Section 2.4 in a manner that (i) excuses such Party from any of its obligations specifically enumerated under this Agreement;
(ii) expands the obligations of the other Party under this Agreement; (iii) negates any consent rights or other rights specifically
allocated to the other Party under this Agreement; (iv) purports to resolve any dispute involving the breach or alleged breach
of this Agreement; (v) resolves a matter if the provisions of this Agreement specify that mutual agreement is required for such
matter; or (vi) would require the other Party to perform any act that is inconsistent with applicable law.

 

ARTICLE
3

License Grants

 

3.1                  
Licenses to Synthetic.

 

(a)              
Subject to the terms and conditions of this Agreement, Intrexon hereby grants to Synthetic a license under the
Intrexon IP to research, develop, use, import, export, make, have made, sell, and offer for sale Synthetic Products in the Field
in the Territory. Such license shall be exclusive (even as to Intrexon) with respect to any clinical development, selling, offering
for sale or other Commercialization of Synthetic Products in the Field, and shall be otherwise non-exclusive.

 

    	12

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

(b)              
Subject to the terms and conditions of this Agreement, Intrexon hereby grants to Synthetic a non-exclusive, royalty-free
license to use and display the Intrexon Trademarks, solely in connection with the Commercialization of Synthetic Products, in the
promotional materials, packaging, and labeling for Synthetic Products, as provided under and in accordance with Section 4.9.

 

(c)               
For purposes of clarity, the licenses from Intrexon to Synthetic under Sections 3.1(a) and 3.1(b) will automatically
change in conjunction with any amendments to the definition of Field in accord with Sections 2.1(c) through 2.1(e).

 

3.2                  
Sublicensing. Except as provided below, Synthetic shall not sublicense the rights granted under Section
3.1 to any Third Party, or transfer the Intrexon Materials to any Third Party, or otherwise grant any Third Party the right to
research, develop, use, or Commercialize Synthetic Products or use or display the Intrexon Trademarks, in each case except with
Intrexon’s written consent, which written consent may be withheld in Intrexon’s sole discretion. Notwithstanding the
foregoing, Synthetic shall have a limited right to sublicense under the circumstances described in Sections 3.2(a) and 3.2(b).

 

(a)              
Synthetic may transfer, to the extent reasonably necessary, Intrexon Materials that are or express active pharmaceutical
ingredients to a Third Party contractor performing contract manufacturing, fill, and/or finish responsibilities for Synthetic Products,
and may in connection therewith grant limited sublicenses necessary to enable such Third Party to perform such activities. If Synthetic
transfers any Intrexon Materials under this Section 3.2(a), Synthetic will remain obligated to ensure that the rights of Intrexon
in and to the Intrexon Materials and Intrexon IP and under the provisions of Articles 6 and 7 of this Agreement are not violated
by any such Third Party contractor.

 

(b)              
Synthetic may, with Intrexon’s written consent, which consent cannot be unreasonably withheld, sublicense
the rights granted under Section 3.1 to an Affiliate, or transfer the Intrexon Materials to an Affiliate, or grant an Affiliate
the right to research, develop, use, or Commercialize Synthetic Products or use or display the Intrexon Trademarks. In the event
that Intrexon consents to any such grant or transfer to an Affiliate, Synthetic shall remain responsible for, and be guarantor
of, the performance by any such Affiliate and shall cause such Affiliate to comply with the provisions of this Agreement in connection
with such performance (as though such Affiliate were Synthetic), including any payment obligations owed to Intrexon hereunder.

 

3.3                  
Limitation on Sublicensees. None of the enforcement rights under the Intrexon Patents that are granted
to Synthetic pursuant to Section 6.3 shall be transferred to, or exercised by, a sublicensee except with Intrexon’s prior
written consent, which may be withheld in Intrexon’s sole discretion.

 

    	13

    	 

    
 EXECUTION
COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

3.4                  
No Non-Permitted Use. Synthetic hereby covenants that it shall not, nor shall it permit any Affiliate
or, if applicable, (sub)licensee, to use or practice, directly or indirectly, any Intrexon IP, Intrexon Channel Technology, or
Intrexon Materials for any purposes other than those expressly permitted by this Agreement.

 

3.5                  
Exclusivity. Intrexon and Synthetic mutually agree that, under the channel collaboration established by
this Agreement, it is intended that the Parties will be exclusive to each other in the Field. To this end, neither Intrexon nor
its Affiliates shall make the Intrexon Channel Technology or Intrexon Materials available to any Third Party for the purpose of
developing or Commercializing products in the Field (except as set forth in Section 3.2), and neither Intrexon nor any Affiliate
shall pursue (either by itself or with a Third Party or Affiliate) the research, development or Commercialization of any product
for purpose of sale in the Field, outside of the Anti-Infectives Program. Further, other than Synthetic’s activities within
the Anti-Infectives Program, neither Synthetic nor its Affiliates shall pursue (either by itself or with a Third Party or Affiliate)
the research, development or Commercialization of any product for purpose of sale in the Field.

 

3.6                  
Off Label Use. For purpose of clarity, (a) following the Commercial Sale of a Synthetic Product, the use
by direct or indirect purchasers or other users of Synthetic Products outside the Field (i.e. “off label use”) shall
not constitute a breach by Synthetic of the terms of Section 3.3, 3.4 or 3.5, provided that neither Synthetic nor its Affiliate
(nor any Third Party under contract with either of them) marketed or promoted Synthetic Products for such off-label use; and (b)
following the Commercial Sale of a product by Intrexon, an Intrexon Affiliate, or a Third Party sublicensee, collaborator, or partner
of Intrexon, the use by direct or indirect purchasers or other users of such products in the Field (i.e. “off label use”)
shall not constitute a breach by Intrexon of the terms of Section 3.5, provided that neither Intrexon nor its Affiliate (nor any
Third Party under contract with either of them) marketed or promoted such products for such off-label use.

 

3.7                  
No Prohibition on Intrexon. Except as explicitly set forth in Sections 3.1 and 3.5, nothing in this Agreement
shall prevent Intrexon from practicing or using the Intrexon Materials, Intrexon Channel Technology, and Intrexon IP for any purpose,
and to grant to Third Parties the right to do the same. Without limiting the generality of the foregoing, Synthetic acknowledges
that Intrexon has all rights, in Intrexon’s sole discretion, to make the Intrexon Materials, Intrexon Channel Technology
(including any active pharmaceutical ingredient used in a Synthetic Product), and Intrexon IP available to Third Party channel
partners or collaborators for use in fields outside the Field.

 

    	14

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

3.8                  
Rights to Clinical and Regulatory Data. Synthetic shall own and control all clinical data and regulatory
filings relating to Commercialization of Synthetic Products during the Term. Synthetic shall provide at Intrexon’s request
full copies of all clinical and non-clinical data and reports, regulatory filings, and communications from regulatory authorities
that relate specifically and solely to Synthetic Products. To the extent that there exist any clinical and non-clinical data and
reports, regulatory filings, and communications from regulatory authorities owned by Synthetic that relate both to Synthetic Products
and other products produced by Synthetic outside the Field, Synthetic shall provide to Intrexon upon Intrexon’s request copies
of the portions of such data, reports, filings, and communications that relate to Synthetic Products. Subject to its ongoing obligations
of exclusivity under Section 3.5 and regarding off label use under 3.6, Intrexon shall be permitted, directly or in conjunction
with or through partners or other channel collaborators, to reference this data, reports, filings, and communications relating
to Synthetic Products in regulatory filings made to obtain regulatory approval for products indicated for use in fields outside
the Field. Intrexon shall have the right to use any such information in developing and Commercializing products outside the Field
and to license any Third Parties to do so. Notwithstanding the provisions of this Section 3.8, Intrexon shall not, outside of the
Anti-Infectives Program, utilize knowingly any Synthetic clinical and non-clinical data or reports in support of obtaining regulatory
approval for a product for use in the Field.

 

3.9                  
Third Party Licenses.

 

(a)              
[*****]shall obtain, [*****], any licenses from Third Parties that are required in order to practice the Intrexon
Channel Technology in the Field where the licensed intellectual property is reasonably necessary for Intrexon to identify and characterize
human antibodies (but specifically excluding intellectual property directed to any processes or methods for expressing monoclonal
antibodies from cloned cells or methods of treating humans with antibodies for purposes of therapy) (“Supplemental In-Licensed
Third Party IP”). Other than with respect to Supplemental In-Licensed Third Party IP, [*****] shall be solely responsible
for obtaining, [*****], any licenses from Third Parties that [*****] determines, in its sole discretion, are required in order
to lawfully make, use, sell, offer for sale, or import Synthetic Products (“Complementary In-Licensed Third Party IP”).
Supplemental In-Licensed Third Party IP and Complementary In-Licensed Third Party IP are collectively referred to as “In-Licensed
Program IP”.

 

(b)              
In the event that either Party desires to license from a Third Party any Supplemental In-Licensed Third Party
IP or Complementary In-Licensed Third Party IP, such Party shall so notify the other Party, and the IPC shall discuss such In-Licensed
Program IP and its applicability to the Synthetic Products and to the Field. As provided above in Section 3.9(a), [*****] shall
have the sole right and responsibility to pursue a license under Supplemental In-Licensed Third Party IP, and [*****] hereby covenants
that it shall not itself directly license such Supplemental In-Licensed Third Party IP at any time, provided that
[*****] may (but shall not be obligated to) obtain such a license directly if the Third Party owner or licensee of such Supplemental
In-Licensed Third Party IP brings an infringement action against [*****] or its Affiliates and, after written notice to [*****]
of such action, [*****] fails to obtain a license to such Supplemental In-Licensed Third Party IP using Diligent Efforts within
ninety (90) days after such notice. Following the IPC’s discussion of any Complementary In-Licensed Third Party IP, subject
to Section 3.8(c), [*****] shall have the right to pursue a license under Complementary In-Licensed Third Party IP, [*****]. For
the avoidance of doubt, [*****] may at any time obtain a license under Complementary In-Licensed Third Party IP outside the Field,
[*****], provided that if [*****] decides to seek to obtain such a license, it shall use reasonable efforts to coordinate
its licensing activities in this regard with [*****].

 

    	15

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

(c)               
[*****] shall provide the proposed terms of any license under Complementary In-Licensed Third Party IP and the
final version of the definitive license agreement for any Complementary In-Licensed Third Party IP to the IPC for review and discussion
prior to signing, and shall consider [*****] comments thereto in good faith. To the extent that [*****] obtains a license under
Supplemental In-Licensed Third Party IP, [*****] shall provide the final version of the definitive license agreement for such Supplemental
In-Licensed Third Party IP to the IPC. If [*****] acquires rights under any In-Licensed Program IP outside the Field, it will do
so on a non-exclusive basis unless it obtains the prior written consent of [*****] for such license outside the Field to be exclusive.
For purposes of clarity, the foregoing requirement shall not restrict [*****]ability with respect to licensing intellectual property
owned by a Third Party that is not required in order for [*****]to lawfully make, use, sell, offer for sale, or import Synthetic
Products. Any Party that is pursuing a license to any In-Licensed Program IP with respect to the Field under this Section 3.9 shall
keep the other Party reasonably informed of the status of any negotiations relating thereto. For purposes of clarity, (i) any costs
incurred by [*****]in obtaining and maintaining licenses to Supplemental In-Licensed Third Party IP shall be borne solely by [*****],
and (ii) any costs incurred by [*****]in obtaining and maintaining licenses to Complementary In-Licensed Third Party IP (and, to
the limited extent provided in subsection (b), Supplemental In-Licensed Third Party IP) shall be borne solely by [*****].

 

(d)              
For any Third Party license under which Synthetic or its Affiliates obtain a license under Patents claiming inventions
or know-how specific to or used or incorporated into the development, manufacture, and/or Commercialization of Synthetic Products,
Synthetic shall use commercially reasonable efforts to ensure that Synthetic will have the ability, pursuant to Section 10.4(h),
to assign such agreement to Intrexon or grant a sublicense to Intrexon thereunder (having the scope set forth in Section 10.4(h)).

 

(e)               
The licenses granted to Synthetic under Section 3.1 may include sublicenses under Intrexon IP that has been licensed
to Intrexon by one or more Third Parties. Any such sublicenses are subject to the terms and conditions set forth in the applicable
upstream license agreement, subject to the cost allocation set forth in Section 3.9(c), provided that Intrexon shall
either provide unredacted copies of such upstream license agreements to Synthetic or shall disclose in writing to Synthetic all
of such terms and conditions that are applicable to Synthetic. Synthetic shall not be responsible for complying with any provisions
of such upstream license agreements unless, and to the extent that, such provisions have been disclosed to Synthetic as provided
in the preceding sentence.

 

(f)               
If either Party receives notice from a Third Party concerning activities of a Party taken in conjunction with
performance of obligations under this Agreement, which notice alleges infringement by a Party of, or offers license under, Patents
or other intellectual property rights owned or controlled by that Third Party, the receiving Party shall inform the other party
thereof within five (5) business days.

 

    	16

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

3.10              
Licenses to Intrexon. Subject to the terms and conditions of this Agreement, Synthetic hereby grants to
Intrexon a non-exclusive, worldwide, fully-paid, royalty-free license, under any applicable Patents or other intellectual property
Controlled by Synthetic or its Affiliates, solely to the extent necessary for Intrexon to conduct those responsibilities assigned
to it under this Agreement, which license shall be sublicensable solely to Intrexon’s Affiliates or to any of Intrexon’s
permitted subcontractors.

 

3.11              
Restrictions Relating to Intrexon Materials. Synthetic and its permitted sublicensees shall use the Intrexon
Materials solely for purposes of the Anti-Infectives Program and not for any other purpose without the prior written consent of
Intrexon. With respect to the Intrexon Materials comprising Intrexon’s vector assembly technology, Synthetic shall not, and
shall ensure that Synthetic personnel and permitted sublicensees do not, except as otherwise permitted in this Agreement (a) distribute,
sell, lend or otherwise transfer such Intrexon Materials to any Third Party; (b) co-mingle such Intrexon Materials with any other
proprietary biological or chemical materials without Intrexon’s written consent; or (c) analyze such Intrexon Materials or
in any way attempt to reverse engineer or sequence such Intrexon Materials.

 

ARTICLE
4

Other Rights and Obligations

 

4.1                  
Development and Commercialization. Subject to Sections 4.6 and 4.7, Synthetic shall be solely responsible
for the performance of the Anti-Infectives Program and the development and Commercialization of Synthetic Products in the Field.
Synthetic shall be responsible for all costs incurred in connection with the Anti-Infectives Program except that Intrexon shall
be responsible for the following: (a) costs of basic research with respect to the Intrexon Channel Technology and Intrexon Materials
(i.e., platform improvements) but, for clarity, excluding research described in Section 4.7 or research requested by the JSC for
the development of a Synthetic Product (which research costs shall be reimbursed by Synthetic); (b) [*****]; and (c) costs of filing,
prosecution and maintenance of Intrexon Patents. The costs encompassed within subsection (a) above shall include the scale-up of
Intrexon Materials and related active pharmaceutical ingredients for clinical trials and commercialization of Synthetic Products
undertaken pursuant to Section 4.6, which shall be at Intrexon’s cost whether it elects to conduct such efforts internally
or through Third Party contractors retained by either Intrexon or Synthetic (with Intrexon’s consent).

 

4.2                  
Transfer of Technology and Information. The JSC shall develop a plan and protocol for each project and
timing for the transfer of relevant data and materials between the Parties.

 

    	17

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

4.3                  
Information and Reporting. Synthetic will keep Intrexon informed about Synthetic’s efforts to develop
and commercialize Synthetic Products, including reasonable and accurate summaries of Synthetic’s (and its Affiliates’
and, if applicable, (sub)licensees’) global development plans (as updated), including preclinical, clinical and regulatory
plans, global marketing plans (as updated), progress towards meeting the goals and milestones in such plans and explanations of
any material deviations, and significant developments in the development and/or commercialization of the Synthetic Products, including
initiation or completion of a clinical trial, submission of a United States or international regulatory filing, receipt of a response
to such United States or international regulatory filing, clinical safety event, receipt of Regulatory Approval, or commercial
launch. As set forth in Section 3.8 above, Synthetic shall also provide to Intrexon copies of all final preclinical protocols and
reports, final clinical protocols and reports, and regulatory correspondence and filings generated by Synthetic as soon as practical
after they become available. Intrexon will keep Synthetic informed about Intrexon’s efforts (a) to establish manufacturing
capabilities and facilities for Synthetic Products (and Intrexon Materials relevant thereto) and otherwise perform its manufacturing
responsibilities under Section 4.6 and (b) to undertake discovery-stage research for the Anti-Infectives Program with respect to
the Intrexon Channel Technology and Intrexon Materials. Unless otherwise provided herein, such disclosures by Synthetic and Intrexon
will be made in the course of JSC meetings at least once every six (6) months while Synthetic Products are being developed or commercialized
anywhere in the world, and shall be reflected in the minutes of such meetings.

 

4.4                  
Regulatory Matters. At all times after the Effective Date, Synthetic shall own and maintain, at its own
cost, all regulatory filings and regulatory approvals for Synthetic Products that Synthetic is developing or Commercializing pursuant
to this Agreement. As such, Synthetic shall be responsible for reporting all adverse events related to such Synthetic Products
to the appropriate regulatory authorities in the relevant countries, in accordance with the applicable laws and regulations of
such countries. To the extent that Intrexon will itself develop, or in collaboration with other third parties develop, Intrexon
Materials outside of the Field, Intrexon may request that Synthetic and Intrexon establish and execute a separate safety data exchange
agreement, which agreement will address and govern the timely exchange of safety information generated by Synthetic, Intrexon,
and relevant third parties with respect to specific Intrexon Materials. The decision to list or not list Patents in any regulatory
filing for a Synthetic Product (for example, as required by 21 C.F.R. § 314.53(b)), add or delete a Patent from a regulatory
filing, or to otherwise identify a Patent to a third party in compliance with laws or regulations relating to regulatory approvals
(for example, in compliance with 42 U.S.C. § 262(a)(1)(A)(k) et seq.) shall be determined by Intrexon, after consultation
with Synthetic, except with respect to Product Specific Program Patents, which will be mutually determined by the Parties.

 

4.5                  
Diligence.

 

(a)              
Synthetic shall use, and shall require its sublicensees to use, Diligent Efforts to develop and commercialize
Synthetic Products.

 

    	18

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

(b)              
Without limiting the generality of the foregoing, Intrexon may, from time to time, notify Synthetic that it believes
it has identified a Superior Therapy, and in such case Intrexon shall provide to Synthetic its then-available information about
such therapy and reasonable written support for its conclusion that the therapy constitutes a Superior Therapy. Synthetic shall
have the following obligations with respect to such proposed Superior Therapy: (i) within sixty (60) days after such notification,
Synthetic shall prepare and deliver to the JSC for review and approval a development plan detailing how Synthetic will pursue the
Superior Therapy (including a proposed budget); (ii) Synthetic shall revise the development plan as directed by the JSC; and (iii)
following approval of the development plan by the JSC, Synthetic shall use Diligent Efforts to pursue the development of the Superior
Therapy under the Anti-Infectives Program in accordance with such development plan. If Synthetic fails to comply with the foregoing
obligations, or if Synthetic unreasonably exercises its casting vote at the JSC to either (x) prevent the approval of a development
plan for a Superior Therapy; (y) delay such approval more than sixty (60) days after delivery of the development plan to the JSC;
or (z) approve a development plan that is insufficient in view of the nature and magnitude of the opportunity presented by the
Superior Therapy, then Intrexon shall have the termination right set forth in Section 10.2(c) (subject to the limitation set forth
therein). For clarity, any dispute arising under this 4.5, including any dispute as to whether a proposed project constitutes a
Superior Therapy (as with any other dispute under this Agreement) shall be subject to dispute resolution in accordance with Article
11.

 

(c)               
The activities of Synthetic’s Affiliates and any permitted sublicensees shall be attributed to Synthetic
for the purposes of evaluating Synthetic’s fulfillment of the obligations set forth in this Section 4.5.

 

4.6                  
Manufacturing.

 

(a)              
As part of the Therapeutic Program, Intrexon shall be tasked with the development of one or more cell lines and
may be asked by the JSC or CMCC to research and develop processes, and may thereafter validate such processes, for manufacturing
one or more Synthetic Products hereunder. In connection with such research and development, a Third Party selected by Synthetic
and approved by the JSC, which approval cannot be unreasonably withheld, may manufacture and supply pre-clinical quantities of
each Synthetic Product. Intrexon shall provide, subject to reasonable controls concerning protecting all provided Intrexon Materials,
to Synthetic or the selected Third Party such quantities of cells or other Intrexon Materials reasonable necessary for the pre-commercial
development activities hereunder, at Synthetic expense, said expense approved in advance by written confirmation of the JSC.

 

(b)              
Intrexon shall have the option to present a proposal for consideration to the JSC to be the manufacturer of the
Synthetic Product, or component thereof, either in bulk form or as finished product, for Synthetic for clinical and/or commercialization
use. Synthetic will determine whether Intrexon, or Synthetic’s or Intrexon’s proposed Third Party, is a manufacturer
of a Synthetic Product. Synthetic shall make their determination as to the manufacturer of each Synthetic Product based on the
commercially reasonable consideration of their standards and criteria, as applied in a manner consistent with that applied to the
manufacture of other Synthetic products and in good faith. Upon Intrexon’s request, Synthetic shall provide Intrexon with
a reasonable explanation and summary of the criteria that Synthetic used in deciding upon the manufacturer(s). In the event Intrexon
is chosen by Synthetic to manufacture Synthetic Product under this Agreement, such supply shall be carried out under the terms
negotiated by the Parties in good faith and set forth in separate supply and quality agreements.

 

    	19

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

(c)               
In the event that Intrexon is not selected as the manufacturer for clinical and/or commercial quantities of a
Synthetic Product, Synthetic will assume all responsibility and related expense for manufacturing and supply of clinical and/or
commercial quantities of such Synthetic Product in accordance with a validation process. Intrexon shall work with Synthetic to
coordinate the transfer to Synthetic, or Synthetic-designated contract manufacturer(s), any process developed to date, along with
any additional Confidential Information or materials Controlled by Intrexon that is necessary for the manufacturing of such bulk
drug substance and/or finished product for the sole purpose of manufacturing such bulk drug substance and/or finished product on
behalf of Synthetic for use in connection with Synthetic’s exercise of its rights in the Field. The reasonable costs and
expenses incurred by Intrexon in carrying out such transfer shall be borne by Synthetic and shall be negotiated in good faith by
the Parties at the time Synthetic exercises its rights under this Agreement. Synthetic, in consultation with Intrexon, will oversee
process validation of such Synthetic Products at the Synthetic selected manufacturing site(s). The process, along with any additional
manufacturing Information transferred hereunder to Synthetic or its contract manufacturer shall be deemed Confidential Information
of Intrexon, and shall not be further transferred to any Third Party or Synthetic Affiliate without the prior written consent of
Intrexon. Any such changes to the process provided by Intrexon to Synthetic are owned by Intrexon, with Synthetic having a non-exclusive
license right (such non-exclusive right hereby granted to Synthetic by Intrexon) for purposes of exercising rights in the Field,
pursuant to this Section 4.6.

 

4.7                  
Support Services. As set forth in Section 2.1(b), immediately following the Effective Date, Intrexon will
begin providing support services to Synthetic by which Intrexon will conduct research and development of Synthetic Products on
behalf of Synthetic for the Primary Program Targets. The JSC will meet promptly following the Effective Date and establish a plan
for this research and development, and Synthetic will compensate Intrexon for such support services with cash payments equal to
Intrexon’s Fully Loaded Cost in connection with such services. Additionally, from time to time, on an ongoing basis, Synthetic
shall request, or Intrexon may propose, that Intrexon perform certain additional support services with respect to the Anti-Infectives
Program. To the extent that the Parties mutually agree that Intrexon should perform such additional services, the Parties shall
negotiate in good faith the terms under which services would be performed, it being understood that Intrexon would be compensated
for such services by cash payments equal to Intrexon’s Fully Loaded Cost in connection with such services. The JSC from time
to time may reasonably determine that specific experiments under the Anti-Infectives Program require special therapeutic or technical
expertise and thus should be conducted by Third Parties having such capabilities. Upon agreement by the Parties, the billing for
any such work conducted by Third Party under the previous sentence may be billed directly to Synthetic or passed through to Synthetic.

 

    	20

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

4.8                  
Compliance with Law. Each Party shall comply, and shall ensure that its Affiliates, (sub)licensees and
Third Party contractors comply, with all applicable laws, regulations, and guidelines applicable to the Anti-Infectives Program,
including without limitation those relating to the transport, storage, and handling of Intrexon Materials and Synthetic Products.

 

4.9                  
Trademarks and Patent Marking. To the extent permitted by applicable law and regulations, Synthetic shall,
and shall ensure that the packaging, promotional materials, and labeling for Synthetic Products shall carry, in a conspicuous location,
the applicable Intrexon Trademark(s), subject to Synthetic’s reasonable approval of the size, position, and location thereof.
Consistent with the U.S. patent laws, Synthetic shall ensure that Synthetic Products, or its packaging or accompanying literature
as appropriate, bear applicable and appropriate patent markings for Intrexon Patent numbers. Synthetic shall provide Intrexon with
copies of any materials containing the Intrexon Trademarks or patent markings prior to using or disseminating such materials, in
order to obtain Intrexon’s approval thereof. Synthetic’s use of the Intrexon Trademarks and patent markings shall be
subject to prior review and approval of the IPC. Synthetic acknowledges Intrexon’s sole ownership of the Intrexon Trademarks
and agrees not to take any action inconsistent with such ownership. Synthetic covenants that it shall not use any trademark confusingly
similar to any Intrexon Trademarks in connection with any products (including any Synthetic Product). From time to time during
the Term, Intrexon shall have the right to obtain from Synthetic samples of Synthetic Product sold by Synthetic or its Affiliates
or sublicensees, or other items which reflect public uses of the Intrexon Trademarks or patent markings, for the purpose of inspecting
the quality of such Synthetic Products, the use of the Intrexon Trademarks, or the accuracy of the patent markings. In the event
that Intrexon inspects under this Section 4.9, Intrexon shall notify the result of such inspection to Synthetic in writing thereafter.
Synthetic shall comply with reasonable policies provided by Intrexon from time-to-time to maintain the goodwill and value of the
Intrexon Trademarks.

 

4.10              
Reporting Compliance. During the Term, in the event that Intrexon notifies Synthetic that Intrexon has
reasonably concluded, after consultation with its outside advisors, that Intrexon will have to consolidate Synthetic’s financial
statements with its own, for so long as Intrexon reasonably believes that such consolidation is necessary, Synthetic shall use
its best efforts to comply with the following additional obligations:

 

(a)              
Synthetic shall maintain at its principal place of business or, upon notice to Intrexon, at such other place
as Synthetic shall determine:

 

(i)                
a copy of Synthetic’s certificate of incorporation or organizational document and all amendments thereto, together
with executed copies of any powers of attorney pursuant to which any amendment has been executed;

 

    	21

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

(ii)              
a copy of this Agreement;

 

(iii)            
a copy of Synthetic’s federal, state, and local income tax returns and reports, if any; and

 

(iv)            
minutes of meetings of Synthetic’s board of directors and shareholders or actions by written consent in lieu
thereof, redacted as necessary by Synthetic to exclude any sensitive or confidential information that Intrexon, by operation of
law or contractual stipulation, is not permitted to receive.

 

(b)              
Synthetic shall use the accrual method of accounting in preparation of its annual reports and for tax purposes
and shall keep its books and records accordingly, consistent with US GAAP.

 

(c)               
Intrexon at its own expense and upon reasonable notice, may examine any information it may reasonably request
(including, to the extent Synthetic has the right to provide such, the work papers of Synthetic’s internal and independent
auditors) and make copies of and abstracts from the financial and operating records and books of account of Synthetic, and discuss
the affairs, finances and accounts of Synthetic with Synthetic and independent auditors of Synthetic, all at such reasonable times
and as often as Intrexon or any agents or representatives of Intrexon may reasonably request. The rights granted pursuant to this
Section 4.10(c) are expressly subject to compliance by Intrexon with the safety, security and confidentiality procedures and guidelines
of Synthetic, as such procedures and guidelines may be established from time to time.

 

(d)              
As soon as available but no later than ninety (90) days after the end of each fiscal year, Synthetic shall cause
to be prepared and Intrexon to be furnished with an audited balance sheet as of the last day of such fiscal year and an audited
income statement, a statement of stockholders’ equity and statement of cash flows for Synthetic for such fiscal year and
notes associated with each, in each case prepared in accordance with US GAAP, together with a report of Synthetic’s independent
auditor that such statements have been prepared in accordance with US GAAP and present fairly, in all material respects, the financial
position, results of operations and cash flows of Synthetic.

 

(e)               
As soon as available but no later than forty five (45) days after the end of each calendar quarter, Synthetic
shall furnish the following to Intrexon an unaudited balance sheet as of the last day of such period, and an unaudited income statement,
a statement of cash flows and a statement of stockholders’ equity for Synthetic for such period, in each case prepared in
accordance with US GAAP.

 

(f)               
As requested by Intrexon on no more than a quarterly basis, a certificate, executed by the Executive Officer
of Synthetic, certifying the following:

 

    	22

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

(i)                
Synthetic maintains accurate books and records reflecting its assets and liabilities and maintains proper and adequate
internal accounting controls that provide assurance that (1) transactions are executed with management’s authorization; (2)
transactions are recorded as necessary to permit preparation of the consolidated financial statements of Synthetic and to maintain
accountability for Synthetic’s consolidated assets; (3) access to the assets of Synthetic is permitted only in accordance
with management’s authorization; (4) the reporting of assets of Synthetic is compared with existing assets at regular intervals;
and (5) accounts, notes and other receivables and inventory are recorded accurately, and proper and adequate procedures are implemented
to effect the collection of accounts, notes and other receivables on a current and timely basis.

 

(ii)              
Synthetic maintains disclosure controls and procedures to the extent such would be required of a publicly registered
company under the Securities Exchange Act of 1934, as amended, and the rules and regulations promulgated thereunder; any such controls
and procedures are effective to ensure that all material information concerning Synthetic is made known on a timely basis to those
individuals responsible for the preparation of any filings that may be required to be made by Intrexon with the SEC and other public
disclosure documents.

 

(g)              
Synthetic shall promptly prepare and furnish to Intrexon any information, whether written or oral, requested
by Intrexon that is reasonably necessary for purposes of Intrexon’s ongoing compliance with applicable law.

 

4.11              
Modification of Deadlines. The parties agree that the delivery deadlines in Section 4.10 will be modified
to the extent necessary to ensure that such deliverables are provided by Synthetic no less than thirty (30) days prior (inclusive
of any cure period set forth in Section 10.2(a)) to the date necessary for Intrexon to meet any disclosure obligation under rules
or regulations to which Intrexon may be or become subject from time to time. Intrexon will provide Synthetic with notice as promptly
as practicable regarding any changes in Intrexon’s disclosure obligations that would require a change in delivery deadlines
or cure periods under this Section 4.11.

 

ARTICLE
5

Compensation

 

5.1                  
Technology Access Fee. In partial consideration for Synthetic’s appointment as an exclusive channel
collaborator in the Field and the other rights granted to Synthetic hereunder, within ten days after receipt of approval from the
NYSE Amex for the listing of the equity referred to below (including any extension should the NYSE Amex require shareholder approval
of such issuance) but in no event later than one hundred twenty (120) days after the Effective Date, Synthetic shall issue to Intrexon
certain equity interests in Synthetic, in accordance with the terms and conditions of that certain Equity Purchase Agreement and
Registration Rights Agreement, each of even date herewith (collectively, the “Equity Agreements”). Provided
that all closing conditions for the Technology Access Fee Shares (as defined in the Equity Agreements) that are within the reasonable
control of Intrexon have been satisfied or waived, the issuance of the Technology Access Fee Shares (as set forth in the Equity
Agreements) is a condition subsequent to the effectiveness of this Agreement.

 

    	23

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

5.2                  
Milestones.

 

(a)              
Synthetic Equity-Based Milestones. Upon the attainment of certain milestone events by each different Synthetic
Product, Synthetic has agreed to issue to Intrexon certain equity interests of Synthetic, or at Synthetic’s election make
a cash payment to Intrexon at the fair market value of the equity interests, as set forth in the Equity Agreements. The specific
milestone events and respective amounts due to Intrexon upon achievement of the milestone events are set forth in the Equity Agreements.

 

5.3                  
Equity Agreements Control. All issuances of equity interests to Intrexon, or cash payments to Intrexon
in lieu of equity, shall be in accordance with the terms and conditions of the Equity Agreements, which Equity Agreements shall
control to the extent they may conflict with Sections 5.1 through 5.2 of this Agreement.

 

5.4                  
Revenue Sharing.

 

(a)              
No later than thirty (30) days after each calendar quarter in which there are positive Net Sales arising from
the sale of any Synthetic Product in the Field in the Territory, Synthetic shall pay to Intrexon on a Synthetic Product-by-Synthetic
Product basis a [xxxx] royalty on the first [xxxx] of annual Net Sales, and a [xxxx] royalty on the
portion of annual Net Sales exceeding [xxxx.] Commencing with the Effective Date, in the event that
are negative Net Sales for a particular Synthetic Product in any calendar quarter, neither Synthetic nor Intrexon shall owe any
payments hereunder with respect to such Synthetic Product. Any negative Net Sales that results from Excess Product Liability Costs
may be carried forward to future quarters and offset against positive Net Sales in such future quarters for the same Synthetic
Product. Except as set forth in the preceding sentence, Synthetic shall not be permitted to carry forward any negative Net Sales
to subsequent quarters.

 

(b)              
No later than thirty (30) days after each calendar quarter in which Synthetic or any Synthetic Affiliate receives
Sublicensing Revenue, Synthetic shall pay to Intrexon fifty percent (50%) of such Sublicensing Revenue.

 

5.5                  
Method of Payment. Except for payments payable as and made in the form of equity interests, payments due
to Intrexon under this Agreement shall be paid in United States dollars by wire transfer to a bank in the United States designated
in writing by Intrexon. All references to “dollars” or “$” herein shall refer to United States dollars.

 

5.6                  
Payment Reports and Records Retention. Within thirty (30) days after the end of each calendar quarter
during which Net Sales have been generated, during which Sublicensing Revenue has been received, or during which a negative Net
Sales has occurred, Synthetic shall deliver to Intrexon a written report that shall contain at a minimum for the applicable calendar
quarter:

 

    	24

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

(a)              
gross sales of each Synthetic Product (on a country-by-country basis);

 

(b)              
itemized calculation of Net Sales, showing all applicable deductions;

 

(c)               
itemized calculation of Sublicensing Revenue;

 

(d)              
the amount of any negative Net Sales for the applicable calendar quarter, and any negative Net Sales amount carried
forward from a prior quarter and applied during the present quarter (as per Section 5.4(a));

 

(e)               
the amount of the payment (if any) due pursuant to Section 5.4(a) and/or 5.4(b);

 

(f)               
the amount of taxes, if any, withheld to comply with any applicable law; and

 

(g)              
the exchange rates used in any of the foregoing calculations.

 

For three (3) years after each sale of
Synthetic Product or after incurring any component item incorporated into a calculation of Net Sales, Synthetic shall keep (and
shall ensure that its Affiliates and, if applicable, (sub)licensees shall keep) complete and accurate records of such sales or
component item in sufficient detail to confirm the accuracy of the payment calculations hereunder.

 

5.7                  
Audits.

 

(a)              
Upon the written request of Intrexon, Synthetic shall permit an independent certified public accounting firm
of internationally recognized standing selected by Intrexon, and reasonably acceptable to Synthetic, to have access to and to review,
during normal business hours and upon no less than thirty (30) days prior written notice, the applicable records of Synthetic and
its Affiliates to verify the accuracy and timeliness of the reports and payments made by Synthetic under this Agreement. Such review
may cover the records for sales made in any calendar year ending not more than three (3) years prior to the date of such request.
The accounting firm shall disclose to both Parties whether the royalty reports and/or know-how reports conform to the provisions
of this Agreement and/or US GAAP, as applicable, and the specific details concerning any discrepancies. Such audit may not be conducted
more than once in any calendar year.

 

    	25

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

(b)              
If such accounting firm concludes that additional amounts were owed during such period, Synthetic shall pay additional
amounts, with interest from the date originally due as set forth in Section 5.9, within thirty (30) days of receipt of the accounting
firm’s written report. If the amount of the underpayment is greater than ten percent (10%) of the total amount actually owed
for the period audited, then Synthetic shall in addition reimburse Intrexon for all costs related to such audit; otherwise, Intrexon
shall pay all costs of the audit. In the event of overpayment, any amount of such overpayment shall be fully creditable against
amounts payable for the immediately succeeding calendar quarter(s); provided, however, that such credit cannot be
applied to reduce the amounts payable by Synthetic to Intrexon for any particular calendar quarter by more than [*****] of the
amount otherwise due to Intrexon.

 

(c)               
Intrexon shall (i) treat all information that it receives under this Section 5.7 in accordance with the confidentiality
provisions of Article 7 and (ii) cause its accounting firm to enter into an acceptable confidentiality agreement with Synthetic
obligating such firm to retain all such financial information in confidence pursuant to such confidentiality agreement, in each
case except to the extent necessary for Intrexon to enforce its rights under this Agreement.

 

5.8                  
Taxes. The Parties will cooperate in good faith to obtain the benefit of any relevant tax treaties to
minimize as far as reasonably possible any taxes which may be levied on any amounts payable hereunder. Synthetic shall deduct or
withhold from any payments any taxes that it is required by applicable law to deduct or withhold. Notwithstanding the foregoing,
if Intrexon is entitled under any applicable tax treaty to a reduction of the rate of, or the elimination of, applicable withholding
tax, it may deliver to Synthetic or the appropriate governmental authority (with the assistance of Synthetic to the extent that
this is reasonably required and is expressly requested in writing) the prescribed forms necessary to reduce the applicable rate
of withholding or to relieve Synthetic of its obligation to withhold tax, and Synthetic shall apply the reduced rate of withholding
tax, or dispense with withholding tax, as the case may be, provided that Synthetic has received evidence of Intrexon’s delivery
of all applicable forms (and, if necessary, its receipt of appropriate governmental authorization) at least fifteen (15) days prior
to the time that the payment is due. If, in accordance with the foregoing, Synthetic withholds any amount, it shall make timely
payment to the proper taxing authority of the withheld amount, and send to Intrexon proof of such payment within forty-five (45)
days following that latter payment.

 

5.9                  
Late Payments. Any amount owed by Synthetic to Intrexon under this Agreement that is not paid within the
applicable time period set forth herein shall accrue interest at the lower of (a) two percent (2%) per month, compounded, or (b)
the highest rate permitted under applicable law.

 

ARTICLE
6

Intellectual Property

 

6.1                  
Ownership.

 

(a)              
Subject to the license granted under Section 3.1, all rights in the Intrexon IP shall remain with Intrexon.

 

    	26

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

(b)              
Synthetic and/or Intrexon may solely or jointly conceive, reduce to practice or develop discoveries, inventions,
processes, techniques, and other technology, whether or not patentable, in the course of performing the Anti-Infectives Program
(collectively “Inventions”). Each Party shall promptly provide the other Party with a detailed written description
of any such Inventions that relate to the Field. Inventorship shall be determined in accordance with United States patent laws.

 

(c)               
Intrexon shall solely own all right, title and interest in all Inventions related to Intrexon Channel Technology,
together with all Patent rights and other intellectual property rights therein (the “Channel-Related Program IP”).
Synthetic hereby assigns all of its right, title and interest in and to the Channel-Related Program IP to Intrexon. Synthetic agrees
to execute such documents and perform such other acts as Intrexon may reasonably request to obtain, perfect and enforce its rights
to the Channel-Related Program IP and the assignment thereof.

 

(d)              
Notwithstanding anything to the contrary in this Agreement, any discovery, invention, process, technique, or
other technology, whether or not patentable, that is conceived, reduced to practice or developed by Synthetic solely or jointly
through the use of the Intrexon Channel Technology, Intrexon IP, or Intrexon Materials in breach of the terms and conditions of
this Agreement, together with all patent rights and other intellectual property rights therein, shall be solely owned by Intrexon
and shall be included in the Channel-Related Program IP.

 

(e)               
All information regarding Channel-Related Program IP shall be Confidential Information of Intrexon. Synthetic
shall be under appropriate written agreements with each of its employees, contractors, or agents working on the Anti-Infectives
Program, pursuant to which such person shall grant all rights in the Inventions to Synthetic (so that Synthetic may convey certain
of such rights to Intrexon, as provided herein) and agree to protect all Confidential Information relating to the Anti-Infectives
Program.

 

6.2                  
Patent Prosecution.

 

(a)              
Intrexon shall have the sole right, but not the obligation, to (a) conduct and control the filing, prosecution
and maintenance of the Intrexon Patents, and (b) conduct and control the filing, prosecution, and maintenance of any applications
for patent term extension and/or supplementary protection certificates that may be available as a result of the regulatory approval
of any Synthetic Product. At the reasonable request of Intrexon, Synthetic shall cooperate with Intrexon in connection with such
filing, prosecution, and maintenance, at Intrexon’s expense. Under no circumstances shall Synthetic
(a) file, attempt to file, or assist anyone else in filing, or attempting to file, any Patent application, either in the United
States or elsewhere, that claims or uses or purports to claim or use or relies for support upon an Invention owned by Intrexon,
(b) use, attempt to use, or assist anyone else in using or attempting to use, the Intrexon Know-How, Intrexon Materials, or any
Confidential Information of Intrexon to support the filing of a Patent application, either in the United States or elsewhere, that
contains claims directed to the Intrexon IP, Intrexon Materials, or the Intrexon Channel Technology, or (c) without prior approval
of the IPC, file, attempt to file, or assist anyone else in filing, or attempting to file, any application for patent term extension
or supplementary protection certificate, either in the United States or elsewhere, that relies upon the regulatory approval of
a Synthetic Product.

 

    	27

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

(b)              
Synthetic shall have the sole right, but not the obligation, to conduct and control the filing, prosecution and
maintenance of any Patents claiming Inventions that are owned by Synthetic or its Affiliates and not assigned to Intrexon under
Section 6.1(c) (“Synthetic Program Patents”). At the reasonable request of Synthetic, Intrexon shall cooperate
with Synthetic in connection with such filing, prosecution, and maintenance, at Synthetic’s expense.

 

(c)               
The Prosecuting Party shall be entitled to use patent counsel selected by it and reasonably acceptable to the
non-Prosecuting Party (including in-house patent counsel as well as outside patent counsel) for the prosecution of the Intrexon
Patents and Synthetic Program Patents, as applicable. The Prosecuting Party shall:

 

(i)                
regularly provide the other Party in advance with reasonable information relating to the Prosecuting Party’s
prosecution of Patents hereunder, including by providing copies of substantive communications, notices and actions submitted to
or received from the relevant patent authorities and copies of drafts of filings and correspondence that the Prosecuting Party
proposes to submit to such patent authorities (it being understood that, to the extent that any such information is readily accessible
to the public, the Prosecuting Party may, in lieu of directly providing copies of such information to such other Party, provide
such other Party with sufficient information that will permit such other Party to access such information itself directly);

 

(ii)              
consider in good faith and consult with the non-Prosecuting Party regarding its timely comments with respect to the
same; provided, however, that if, within fifteen (15) days after providing any documents to the non-Prosecuting Party for comment,
the Prosecuting Party does not receive any written communication from the non-Prosecuting Party indicating that it has or may have
comments on such document, the Prosecuting Party shall be entitled to assume that the non-Prosecuting Party has no comments thereon;

 

(iii)            
consult with the non-Prosecuting Party before taking any action that would reasonably be expected to have a material
adverse impact on the scope of claims within the Intrexon Patents and Synthetic Program Patents, as applicable.

 

As used above “Prosecuting Party”
means Intrexon in the case of Intrexon Patents and Synthetic in the case of Synthetic Program Patents.

 

6.3                  
Infringement of Patents by Third Parties.

 

    	28

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

(a)              
Except as expressly provided in the remainder of this Section 6.3, Intrexon shall have the sole right to take
appropriate action against any person or entity directly or indirectly infringing any Intrexon Patent (or asserting that an Intrexon
Patent is invalid or unenforceable) (collectively, “Infringement”), either by settlement or lawsuit or other
appropriate action.

 

(b)              
Notwithstanding the foregoing, Synthetic shall have the first right, but not the obligation, to take appropriate
action to enforce Product-Specific Program Patents against any Infringement that involves a commercially material amount of allegedly
infringing activities in the Field (“Field Infringement”), either by settlement or lawsuit or other appropriate
action. If Synthetic fails to take the appropriate steps to enforce Product-Specific Program Patents against any Field Infringement
within one hundred eighty (180) days of the date one Party has provided notice to the other Party pursuant to Section 6.3(g) of
such Field Infringement, then Intrexon shall have the right (but not the obligation), at its own expense, to enforce Product-Specific
Program Patents against such Field Infringement, either by settlement or lawsuit or other appropriate action.

 

(c)               
With respect to any Field Infringement that cannot reasonably be abated through the enforcement of Product-Specific
Program Patents pursuant to Section 6.3(b) but can reasonably be abated through the enforcement of Intrexon Patent(s) (other than
the Product-Specific Program Patents), Intrexon shall be obligated to choose one of the following courses of action: (i) enforce
one or more of the applicable Intrexon Patent(s) in a commercially reasonable manner against such Field Infringement, or (ii) [*****].
Intrexon and Synthetic shall bear the costs and expenses of such enforcement equally. The determination of which Intrexon Patent(s)
to assert shall be made by Intrexon in its sole discretion; provided, however, that Intrexon shall consult in good faith with Synthetic
on such determination. For the avoidance of doubt, Intrexon has no obligations under this Agreement to enforce any Intrexon Patents
against, or otherwise abate, any Infringement that is not a Field Infringement.

 

(d)              
In the event a Party pursues an action under this Section 6.3, the other Party shall reasonably cooperate with
the enforcing Party with respect to the investigation and prosecution of any alleged, threatened, or actual Infringement, at the
enforcing Party’s expense (except with respect to an action under Section 6.3(c), where all costs and expenses will be shared
equally in accordance with terms thereof).

 

(e)               
Synthetic shall not settle or otherwise compromise any action under this Section 6.3 in a way that diminishes
the rights or interests of Intrexon outside the Field or adversely affects any Intrexon Patent without Intrexon’s prior written
consent, which consent shall not be unreasonably withheld. Intrexon shall not settle or otherwise compromise any action under this
Section 6.3 in a way that diminishes the rights or interests of Synthetic in the Field or adversely affects any Intrexon Patent
with respect to the Field without Synthetic’s prior written consent, which consent shall not be unreasonably withheld.

 

    	29

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

(f)               
Except as otherwise agreed to by the Parties in writing, any settlements, damages or other monetary awards recovered
pursuant to a suit, proceeding, or action brought pursuant to Section 6.3 will be allocated first to the costs and expenses of
the Party controlling such action, and second, to the costs and expenses (if any) of the other Party (to the extent not otherwise
reimbursed), and any remaining amounts (the “Recovery”) will be shared by the Parties as follows: In any action
initiated by Intrexon pursuant to Section 6.3(a) that does not involve Field Infringement, or in any action initiated by Intrexon
pursuant to Section 6.3(b), Intrexon shall retain one hundred percent (100%) of any Recovery. In any action initiated by Synthetic
pursuant to Section 6.3(b), Synthetic shall retain one hundred percent (100%) of any Recovery, but such Recovery shall be shared
with Intrexon as Sublicensing Revenue. In any action initiated by Intrexon or Synthetic pursuant to Section 6.3(c), the Parties
shall share the Recovery equally, and such Recovery shall not be deemed to constitute Sublicensing Revenue.

 

(g)              
Synthetic shall promptly notify Intrexon in writing of any suspected, alleged, threatened, or actual Infringement
of which it becomes aware, and Intrexon shall promptly notify Synthetic in writing of any suspected, alleged, threatened, or actual
Field Infringement of which it becomes aware.

 

ARTICLE
7

Confidentiality

 

7.1                  
Confidentiality. Except to the extent expressly authorized by this Agreement or otherwise agreed in writing
by the Parties, each Party agrees that it shall keep confidential and shall not publish or otherwise disclose and shall not use
for any purpose other than as provided for in this Agreement any Confidential Information disclosed to it by the other Party pursuant
to this Agreement, except to the extent that the receiving Party can demonstrate by competent evidence that specific Confidential
Information:

 

(a)              
was already known to the receiving Party, other than under an obligation of confidentiality, at the time of disclosure
by the other Party;

 

(b)              
was generally available to the public or otherwise part of the public domain at the time of its disclosure to
the receiving Party;

 

(c)               
became generally available to the public or otherwise part of the public domain after its disclosure and other
than through any act or omission of the receiving Party in breach of this Agreement;

 

(d)              
was disclosed to the receiving Party, other than under an obligation of confidentiality to a Third Party, by
a Third Party who had no obligation to the disclosing Party not to disclose such information to others; or

 

    	30

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

(e)               
was independently discovered or developed by the receiving Party without the use of Confidential Information
belonging to the disclosing Party, as documented by the receiving Party’s written records.

 

The foregoing non-use
and non-disclosure obligation shall continue (i) indefinitely, for all Confidential Information that qualifies as a trade secret
under applicable law; or (ii) for the Term of this Agreement and for seven (7) years thereafter, in all other cases.

 

7.2                  
Authorized Disclosure. Notwithstanding the limitations in this Article 7, either
Party may disclose the Confidential Information belonging to the other Party to the extent such disclosure is reasonably
necessary in the following instances:

 

(a)              
complying with applicable laws or regulations or valid court orders, provided
that the Party making such disclosure provides the other Party with reasonable prior written notice of such disclosure and
makes a reasonable effort to obtain, or to assist the other Party in obtaining, a protective order preventing or limiting the disclosure
and/or requiring that the terms and conditions of this Agreement be used only for the purposes for which the law or regulation
required, or for which the order was issued;

 

(b)              
to regulatory authorities in order to seek or obtain approval to conduct clinical trials, or to gain regulatory
approval, of Synthetic Products or any products being developed by Intrexon or its other licensees and/or channel partners or collaborators,
provided that the Party making such disclosure (i) provides the other Party with reasonable opportunity to review any such disclosure
in advance and to suggest redactions or other means of limiting the disclosure of such other Party’s Confidential Information
and (ii) does not unreasonably reject any such suggestions;

 

(c)               
disclosure to investors and potential investors, acquirers, or merger candidates who agree to maintain the confidentiality
of such information, provided that such disclosure is used solely for the purpose of evaluating such investment, acquisition,
or merger (as the case may be);

 

(d)              
disclosure on a need-to-know basis to Affiliates, licensees, sublicensees, employees, consultants or agents (such
as CROs and clinical investigators) who agree to be bound by obligations of confidentiality and non-use at least equivalent in
scope to those set forth in this Article 7; and

 

(e)               
disclosure of the terms of this Agreement by Intrexon to collaborators and other channel partners or collaborators
who agree to be bound by obligations of confidentiality and non-use at least equivalent in scope to those set forth in this Article
7.

 

    	31

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

7.3                  
Publicity; Publications. The Parties agree that the public announcement of the execution of this Agreement
shall be substantially in the form of a press release mutually agreed to by the Parties. Each Party will provide the other Party
with the opportunity to review and comment, prior to submission or presentation, on external reports, publications and presentations
(e.g., press releases, reports to government agencies, abstracts, posters, manuscripts and oral presentations) that refer to the
Anti-Infectives Program or programs that are approved by the JSC. For such reports, publications, and presentations, the disclosing
Party will provide the other Party at least fifteen (15) days for review of the proposed submission or presentation. For reports
and manuscripts, the disclosing Party will provide the other Party at least thirty (30) days for review of the report or manuscript.
The presenting Party will act in good faith to incorporate the comments of the other Party and shall, in any event, redact any
Confidential Information of the other Party and cooperate with the other Party to postpone such submissions or presentations if
necessary to provide the other Party with sufficient time to prepare and file any related Patent applications before the submission
or presentation occurs, as appropriate.

 

7.4                  
Terms of the Agreement. Each Party shall treat the terms of this Agreement as the Confidential Information
of other Party, subject to the exceptions set forth in Section 7.2. Notwithstanding the foregoing, each Party acknowledges that
the other Party may be obligated to file a copy of this Agreement with the SEC, either as of the Effective Date or at some point
during the Term. Each Party shall be entitled to make such a required filing, provided that it requests confidential treatment
of certain commercial terms and sensitive technical terms hereof to the extent such confidential treatment is reasonably available
to it. In the event of any such filing, the filing Party shall provide the other Party with a copy of the Agreement marked to show
provisions for which the filing Party intends to seek confidential treatment and shall reasonably consider and incorporate the
other Party’s comments thereon to the extent consistent with the legal requirements governing redaction of information from
material agreements that must be publicly filed. The other Party shall promptly provide any such comments.

 

7.5                  
Proprietary Information and Operational Audits.

 

(a)              
For the purpose of confirming compliance with the Field-limited licenses granted in Article 3, the diligence
obligations of Article 4, and the confidentiality obligations under Article 7, Synthetic acknowledges that Intrexon’s authorized
representative(s), during regular business hours may (i) examine and inspect Synthetic’s facilities and (ii) inspect all
data and work products relating to this Agreement, subject to restrictions imposed by applicable laws. Any examination or inspection
hereunder shall require five (5) business days written notice from Intrexon to Synthetic. Synthetic will make itself and the pertinent
employees and/or agents available, on a reasonable basis, to Intrexon for the aforementioned compliance review.

 

(b)              
For the purpose of confirming compliance with the diligence obligations of Section 4.6, and the confidentiality
obligations under Article 7, Intrexon acknowledges that Synthetic authorized representative(s), during regular business hours may
(i) examine and inspect Intrexon’s facilities and (ii) inspect all data and work products relating to this Agreement. Any
examination or inspection hereunder shall require five (5) business days written notice from Synthetic to Intrexon. Intrexon will
make itself and the pertinent employees and/or agents available, on a reasonable basis, to Synthetic for the aforementioned compliance
review.

 

    	32

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

(c)               
In view of the Intrexon Confidential Information, Intrexon Know-How, and Intrexon Materials transferred to Synthetic
hereunder, Intrexon from time-to-time, but no more than quarterly, may request that Synthetic confirm the status of the Intrexon
Materials at Synthetic (i.e. how much used, how much shipped, to whom and any unused amounts destroyed (by whom, when) as well
as any amounts returned to Intrexon or destroyed). Within ten (10) business days of Synthetic’s receipt of any such written
request, Synthetic shall provide the written report to Intrexon.

 

7.6                  
Intrexon Commitment. Intrexon shall use reasonable efforts to obtain an agreement with its other licensees
and channel partners or collaborators to enable Synthetic to disclose confidential information of such licensees and channel partners
or collaborators to regulatory authorities in order to seek or obtain approval to conduct clinical trials, or to gain regulatory
approval of, Synthetic Products, in a manner consistent with the provisions of Section 7.2(b).

 

ARTICLE
8

Representations And Warranties

 

8.1                  
Representations and Warranties of Synthetic. Synthetic hereby represents and warrants to Intrexon that,
as of the Effective Date:

 

(a)              
Corporate Power. Synthetic is duly organized and validly existing under the laws of Nevada and has full
corporate power and authority to enter into this Agreement and to carry out the provisions hereof.

 

(b)              
Due Authorization. Synthetic is duly authorized to execute and deliver this Agreement and to perform its
obligations hereunder, and the person executing this Agreement on Synthetic’s behalf has been duly authorized to do so by
all requisite corporate action.

 

(c)               
Binding Agreement. This Agreement is a legal and valid obligation binding upon Synthetic and enforceable
in accordance with its terms, except as such enforcement may be limited by applicable bankruptcy, insolvency, reorganization, arrangement,
moratorium or other similar laws affecting creditors’ rights, and subject to general equity principles and to limitations
on availability of equitable relief, including specific performance. The execution, delivery and performance of this Agreement
by Synthetic does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which
it may be bound. Synthetic is aware of no action, suit or inquiry or investigation instituted by any governmental agency which
questions or threatens the validity of this Agreement.

 

8.2                  
Representations and Warranties of Intrexon. Intrexon hereby represents and warrants to Synthetic that,
as of the Effective Date:

 

    	33

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

(a)              
Corporate Power. Intrexon is duly organized and validly existing under the laws of Virginia and has full
corporate power and authority to enter into this Agreement and to carry out the provisions hereof.

 

(b)              
Due Authorization. Intrexon is duly authorized to execute and deliver this Agreement and to perform its
obligations hereunder, and the person executing this Agreement on Intrexon’s behalf has been duly authorized to do so by
all requisite corporate action.

 

(c)               
Binding Agreement. This Agreement is a legal and valid obligation binding upon Intrexon and enforceable
in accordance with its terms, except as such enforcement may be limited by applicable bankruptcy, insolvency, reorganization, arrangement,
moratorium or other similar laws affecting creditors’ rights, and subject to general equity principles and to limitations
on availability of equitable relief, including specific performance. The execution, delivery and performance of this Agreement
by Intrexon does not conflict with any agreement, instrument or understanding, oral or written, to which it is a party or by which
it may be bound. Intrexon is aware of no action, suit or inquiry or investigation instituted by any governmental agency which questions
or threatens the validity of this Agreement.

 

(d)              
Additional Intellectual Property Representations.

 

(i)                
Intrexon possesses sufficient rights to enable Intrexon to grant all rights and licenses it purports to grant to
Synthetic with respect to the Intrexon Patents under this Agreement;

 

(ii)              
The Intrexon Patents existing as of the Effective Date constitute all of the Patents Controlled by Intrexon as of
such date that are necessary for the development, manufacture and Commercialization of Synthetic Products;

 

(iii)            
Intrexon has not granted, and during the Term Intrexon will not grant, any right or license, to any Third Party under
the Intrexon IP that conflicts with the rights or licenses granted or to be granted to Synthetic hereunder;

 

(iv)            
There is no pending litigation, and Intrexon has not received any written notice of any claims or litigation, seeking
to invalidate or otherwise challenge the Intrexon Patents or Intrexon’s rights therein;

 

(v)              
None of the Intrexon Patents is subject to any pending re-examination, opposition, interference or litigation proceedings;

 

(vi)            
All of the Intrexon Patents have been filed and prosecuted in accordance with all applicable laws and have been maintained,
with all applicable fees with respect thereto (to the extent such fees have come due) having been paid;

 

    	34

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

(vii)          
Intrexon has entered into agreements with each of its current and former officers, employees and consultants involved
in research and development work, including development of the Intrexon’s products and technology providing Intrexon, to
the extent permitted by law, with title and ownership to patents, patent applications, trade secrets and inventions conceived,
developed, reduced to practice by such person, solely or jointly with other of such persons, during the period of employment by
Intrexon (except where the failure to have entered into such an agreement would not have a material adverse effect on the rights
granted to Synthetic herein), and Intrexon is not aware that any of its employees or consultants is in material violation thereof;

 

(viii)        
To Intrexon’s knowledge, there is no infringement, misappropriation or violation by third parties of any Intrexon
Channel Technology or Intrexon IP in the Field;

 

(ix)            
There is no pending or, to Intrexon’s knowledge, threatened action, suit, proceeding or claim by others against
Intrexon that Intrexon infringes, misappropriates or otherwise violates any intellectual property or other proprietary rights of
others in connection with the use of the Intrexon Channel Technology or Intrexon IP, and Intrexon has not received any written
notice of such claim;

 

(x)              
To Intrexon’s knowledge, no employee of Intrexon is the subject of any claim or proceeding involving a violation
of any term of any employment contract, patent disclosure agreement, invention assignment agreement, non-competition agreement,
non-solicitation agreement, non-disclosure agreement or any restrictive covenant to or with a former employer (A) where the basis
of such violation relates to such employee’s employment with Intrexon or actions undertaken by the employee while employed
with Intrexon and (B) where such violation is relevant to the use of the Intrexon Channel Technology in the Field;

 

(xi)            
None of the Intrexon Patents owned by Intrexon or its Affiliates, and, to Intrexon’s knowledge, the Intrexon
Patents licensed to Intrexon or its Affiliates, have been adjudged invalid or unenforceable by a court of competent jurisdiction
or applicable government agency, in whole or in part, and there is no pending or, to Intrexon’s knowledge, threatened action,
suit, proceeding or claim by others challenging the validity or scope of any such Intrexon Patents; and

 

    	35

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

(xii)          
Except as otherwise disclosed in writing to Synthetic, Intrexon: (A) is in material compliance with all statutes,
rules or regulations applicable to the ownership, testing, development, manufacture, packaging, processing, use, distribution,
marketing, labeling, promotion, sale, offer for sale, storage, import, export or disposal of any product that is under development,
manufactured or distributed by Intrexon in the Field (“Applicable Laws”); (B) has not received any FDA Form
483, notice of adverse finding, warning letter, untitled letter or other correspondence or notice from the United States Food and
Drug Administration (the “FDA”) or any other federal, state, local or foreign governmental or regulatory authority
alleging or asserting material noncompliance with any Applicable Laws or any licenses, certificates, approvals, clearances, authorizations,
permits and supplements or amendments thereto required by any such Applicable Laws (“Authorizations”), which
would, individually or in the aggregate, result in a material adverse effect; (C) possesses all material Authorizations necessary
for the operation of its business as described in the Field and such Authorizations are valid and in full force and effect and
Intrexon is not in material violation of any term of any such Authorizations; and (D) since January 1, 2011, (1) has not received
notice of any claim, action, suit, proceeding, hearing, enforcement, investigation, arbitration or other action from the FDA or
any other federal, state, local or foreign governmental or regulatory authority or third party alleging that any product operation
or activity is in material violation of any Applicable Laws or Authorizations and has no knowledge that the FDA or any other federal,
state, local or foreign governmental or regulatory authority or third party is considering any such claim, litigation, arbitration,
action, suit investigation or proceeding; (2) has not received notice that the FDA or any other federal, state, local or foreign
governmental or regulatory authority has taken, is taking or intends to take action to limit, suspend, modify or revoke any material
Authorizations and has no knowledge that the FDA or any other federal, state, local or foreign governmental or regulatory authority
is considering such action; (3) has filed, obtained, maintained or submitted all material reports, documents, forms, notices, applications,
records, claims, submissions and supplements or amendments as required by any Applicable Laws or Authorizations and that all such
reports, documents, forms, notices, applications, records, claims, submissions and supplements or amendments were materially complete
and correct on the date filed (or were corrected or supplemented by a subsequent submission); and (4) has not, either voluntarily
or involuntarily, initiated, conducted, or issued or caused to be initiated, conducted or issued, any recall, market withdrawal
or replacement, safety alert, post sale warning, “dear doctor” letter, or other notice or action relating to the alleged
lack of safety or efficacy of any product or any alleged product defect or violation and, to Intrexon’s knowledge, no third
party has initiated, conducted or intends to initiate any such notice or action.

 

except, in each of (ix) through
(xii), for any instances which would not, individually or in the aggregate, result in a material adverse effect on the rights granted
to Synthetic hereunder or Intrexon’s ability to perform its obligations hereunder.

 

8.3                  
Warranty Disclaimer. EXCEPT FOR THE EXPRESS WARRANTIES PROVIDED IN THIS ARTICLE 8 OR IN THE EQUITY AGREEMENTS,
EACH PARTY HEREBY DISCLAIMS ANY AND ALL OTHER WARRANTIES, EITHER EXPRESS OR IMPLIED, INCLUDING WITHOUT LIMITATION ANY WARRANTIES
OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, OR NONINFRINGEMENT OF THE INTELLECTUAL
PROPERTY RIGHTS OF THIRD PARTIES.

 

    	36

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

ARTICLE
9

Indemnification

 

9.1                  
Indemnification by Intrexon. Intrexon agrees to indemnify, hold harmless, and defend Synthetic and its
Affiliates and their respective directors, officers, employees, and agents (collectively, the “Synthetic Indemnitees”)
from and against any and all liabilities, damages, costs, expenses, or losses (including reasonable legal expenses and attorneys’
fees) (collectively, “Losses”) resulting from any claims, suits, actions, demands, or other proceedings brought
by a Third Party (collectively, “Claims”) to the extent arising from (a) the gross negligence or willful misconduct
of Intrexon or any of its Affiliates, or their respective employees or agents, (b) the use, handling, storage or transport of Intrexon
Materials by or on behalf of Intrexon or its Affiliates, licensees (other than Synthetic) or sublicensees; or (c) breach by Intrexon
of any representation, warranty or covenant in this Agreement. Notwithstanding the foregoing, Intrexon shall not have any obligation
to indemnify the Synthetic Indemnitees to the extent that a Claim arises from (i) the gross negligence or willful misconduct of
Synthetic or any of its Affiliates, licensees, or sublicensees, or their respective employees or agents; or (ii) a breach by Synthetic
of a representation, warranty, or covenant of this Agreement.

 

9.2                  
Indemnification by Synthetic. Synthetic agrees to indemnify, hold harmless, and defend Intrexon, its Affiliates
and Third Security, and their respective directors, officers, employees, and agents (and any Third Parties which have licensed
to Intrexon intellectual property rights within Intrexon IP on or prior to the Effective Date, to the extent required by the relevant
upstream license agreement) (collectively, the “Intrexon Indemnitees”) from and against any Losses resulting
from Claims, to the extent arising from any of the following: (a) the gross negligence or willful misconduct of Synthetic or any
of its Affiliates or their respective employees or agents; (b) the use, handling, storage, or transport of Intrexon
Materials by or on behalf of Synthetic or its Affiliates, licensees, or sublicensees; (c) breach by Synthetic of any material
representation, warranty or covenant in this Agreement; or (d) the design, development, manufacture, regulatory approval, handling,
storage, transport, distribution, sale or other disposition of any Synthetic Product by or on behalf of Synthetic or its Affiliates,
licensees, or sublicensees. Notwithstanding the foregoing, Synthetic shall not have any obligation to indemnify the Intrexon Indemnitees
to the extent that a Claim arises from (i) the gross negligence or willful misconduct of Intrexon or any of its Affiliates, or
their respective employees or agents; or (ii) a breach by Intrexon of a representation, warranty, or covenant of this Agreement.

 

9.3                  
Product Liability Claims. Notwithstanding the provisions of Section 9.2, any Losses arising out of any
Third Party claim, suit, action, proceeding, liability or obligation involving any actual or alleged death or bodily injury arising
out of or resulting from the development, manufacture or Commercialization of any Synthetic Products for use or sale in the Field,
to the extent that such Losses exceed the amount (if any) covered by the applicable Party’s product liability insurance (“Excess
Product Liability Costs”), shall be paid by [*****], except to the extent such Losses arise out of any Third-Party Claim
based on the gross negligence or willful misconduct of a Party, its Affiliates, or its Affiliates’ Sublicensees, or any of
the respective officers, directors, employees and agents of each of the foregoing entities, in the performance of obligations or
exercise of rights under this Agreement.

 

    	37

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

9.4                  
Control of Defense. As a condition precedent to any indemnification obligations hereunder, any entity
entitled to indemnification under this Article 9 shall give written notice to the indemnifying Party of any Claims that may be
subject to indemnification, promptly after learning of such Claim. If such Claim falls within the scope of the indemnification
obligations of this Article 9, then the indemnifying Party shall assume the defense of such Claim with counsel reasonably satisfactory
to the indemnified Party. The indemnified Party shall cooperate with the indemnifying Party in such defense. The indemnified Party
may, at its option and expense, be represented by counsel of its choice in any action or proceeding with respect to such Claim.
The indemnifying Party shall not be liable for any litigation costs or expenses incurred by the indemnified Party without the indemnifying
Party’s written consent, such consent not to be unreasonably withheld. The indemnifying Party shall not settle any such Claim
if such settlement (a) does not fully and unconditionally release the indemnified Party from all liability relating thereto or
(b) adversely impacts the exercise of the rights granted to the indemnified Party under this Agreement, unless the indemnified
Party otherwise agrees in writing.

 

9.5                  
Insurance. Immediately prior to, and during marketing, Synthetic shall maintain in effect and good standing
a product liability insurance policy issued by a reputable insurance company in amounts considered standard for the industry. Immediately
prior to, and during the conduct of any clinical trials, Synthetic shall maintain in effect and good standing a clinical trials
liability insurance policy issued by a reputable insurance company in amounts considered standard for the industry. At Intrexon’s
reasonable request, Synthetic shall provide Intrexon with all details regarding such policies, including without limitation copies
of the applicable liability insurance contracts. Synthetic shall use reasonable efforts to include Intrexon as an additional insured
on any such policies.

 

ARTICLE
10

Term; Termination

 

10.1              
Term. The term of this Agreement shall commence upon the Effective Date and shall continue until terminated
pursuant to Section 10.2 or 10.3 (the “Term”).

 

10.2              
Termination for Material Breach; Termination Under Section 4.5(b)

 

(a)              
Either Party shall have the right to terminate this Agreement upon written notice to the other Party if the other
Party commits any material breach of this Agreement that such breaching Party fails to cure within sixty (60) days following written
notice from the nonbreaching Party specifying such breach; provided, however, that if Synthetic commits any breach of the provisions
of Section 4.10 of this Agreement, Intrexon shall have the right to terminate this Agreement if Synthetic fails after notice from
Intrexon to cure such breach within thirty (30) days following written notice thereof.

 

    	38

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

(b)              
Intrexon shall have the right to terminate this Agreement, at its sole discretion, if any necessary shareholder,
member, exchange, and/or board of director approvals of Synthetic have not been obtained, and the Technology Access Fee Shares
(as defined in the Equity Agreements) have not been issued, within the time frames set forth in Section 5.1.

 

(c)               
Intrexon shall have the right to terminate this Agreement under the circumstances set forth in Section 4.5(b)
upon written notice to Synthetic, such termination to become effective sixty (60) days following such written notice unless Synthetic
remedies the circumstances giving rise to such termination within such sixty (60) day period.

 

(d)              
 Intrexon shall have the right to terminate this Agreement should Synthetic execute any purported assignment
of this Agreement contrary to the prohibitions in Section 12.8, such termination occurring upon Intrexon providing written notice
to Synthetic and becoming effective immediately upon such written notice.

 

10.3              
Termination by Synthetic. Synthetic shall have the right to voluntarily terminate this Agreement in its
entirety upon ninety (90) days written notice to Intrexon at any time, provided that such notice may not be given during the eighteen
(18) month period commencing on the Effective Date.

 

10.4              
Effect of Termination. In the event of termination of this Agreement pursuant to Section 10.2 or Section
10.3, the following shall apply:

 

(a)              
Retained Products. Synthetic shall be permitted to continue the clinical development and Commercialization
in the Field of any Synthetic Product that, at the time of termination, satisfies at least one of the following criteria (a “Retained
Product”):

 

(i)                
the particular Synthetic Product is being sold by Synthetic triggering profit sharing payments therefor under Section
5.4(a) of this Agreement,

 

(ii)              
the particular Synthetic Product has received regulatory approval,

 

(iii)            
the particular Synthetic Product is a subject of an application for regulatory approval in the Field that is pending
before the applicable regulatory authority,

 

(iv)            
the particular Synthetic Product is the subject of at least an ongoing Phase 2 or Phase 3 clinical trial in the Field
(in the case of a termination by Intrexon due to a Synthetic uncured breach pursuant to Section 10.2(a) or a termination by Synthetic
pursuant to Section 10.3).

 

Such right to continue development and
commercialization shall be subject to Synthetic’s full compliance with the payment provisions in Article 5, a continuing
obligation for Synthetic to use in accord with Sections 4.5(a) and 4.5(c) Diligent Efforts to develop and commercialize any Retained
Products, and all other provisions of this Agreement that survive termination.

 

    	39

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

(b)              
Termination of Licenses. Except as necessary for Synthetic to continue to obtain regulatory approval for,
clinically develop, use, manufacture and Commercialize the Retained Products in the Field as permitted by Section 10.4(a), all
rights and licenses granted by Intrexon to Synthetic under this Agreement shall terminate and shall revert to Intrexon without
further action by either Intrexon or Synthetic. Synthetic’s license with respect to Retained Products shall be exclusive
or non-exclusive, as the case may be, on the same terms as set forth in Section 3.1.

 

(c)               
Reverted Products. All Synthetic Products other than the Retained Products shall be referred to herein
as the “Reverted Products.” Synthetic shall immediately cease, and shall cause its Affiliates and, if applicable,
(sub)licensees to immediately cease, all development and Commercialization of the Reverted Products, and Synthetic shall not use
or practice, nor shall it cause or permit any of its Affiliates or, if applicable, (sub)licensees to use or practice, directly
or indirectly, any Intrexon IP with respect to the Reverted Products. Synthetic shall immediately discontinue making any representation
regarding its status as a licensee or channel collaborator of Intrexon with respect to the Reverted Products.

 

(d)              
Intrexon Materials. Synthetic shall promptly return, or at Intrexon’s request, destroy, any Intrexon
Materials in Synthetic’s possession or control at the time of termination other than any Intrexon Materials necessary for
the continued development, regulatory approval, use, manufacture and Commercialization of the Retained Products in the Field.

 

(e)               
Licenses to Intrexon. Synthetic is automatically deemed to grant to Intrexon a worldwide, fully paid,
royalty-free, exclusive (even as to Synthetic and its Affiliates), irrevocable, license (with full rights to sublicense) under
the Synthetic Termination IP, to make, have made, import, use, offer for sale and sell Reverted Products and to use the Intrexon
Channel Technology, the Intrexon Materials, and/or the Intrexon IP in the Field, subject to any exclusive rights held by Synthetic
in Reverted Products pursuant to Section 10.4(c). The Parties shall also take such actions and execute such other instruments and
documents as may be reasonably necessary to document such license to Intrexon.

 

(f)               
Regulatory Filings. Synthetic shall promptly assign to Intrexon, and will provide full copies of, all
regulatory approvals and regulatory filings that relate specifically and solely to Reverted Products. Synthetic shall also take
such actions and execute such other instruments, assignments and documents as may be necessary to effect the transfer of rights
thereunder to Intrexon. To the extent that there exist any regulatory approvals and regulatory filings that relate both to Reverted
Products and other products, Synthetic shall provide copies of the portions of such regulatory filings that relate to Reverted
Products and shall reasonably cooperate to assist Intrexon in obtaining the benefits of such regulatory approvals with respect
to the Reverted Products.

 

    	40

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

(g)              
Data Disclosure. Synthetic shall provide to Intrexon copies of the relevant portions of all material reports
and data, including clinical and non-clinical data and reports, obtained or generated by or on behalf of Synthetic or its Affiliates
to the extent that they relate to Reverted Products, within sixty (60) days of such termination unless otherwise agreed, and Intrexon
shall have the right to use any such Information in developing and commercializing Reverted Products and to license any Third Parties
to do so.

 

(h)              
Third-Party Licenses. At Intrexon’s request, Synthetic shall promptly provide to Intrexon copies
of all Third-Party agreements under which Synthetic or its Affiliates obtained a license under Patents claiming inventions or know-how
specific to or used or incorporated into the development, manufacture and/or commercialization of the Reverted Products. At Intrexon’s
request such that Intrexon may Commercialize the Reverted Products, Synthetic shall promptly work with Intrexon to either (A) assign
to Intrexon the Third Party agreement(s), or (B) grant a sublicense (with an appropriate scope) to Intrexon under the Third Party
agreement(s). Thereafter Intrexon shall be fully responsible for all obligations due for its actions under the sublicensed or assigned
Third Party agreements. Notwithstanding the above, if Intrexon does not wish to assume any financial or other obligations associated
with a particular Third Party agreement identified to Intrexon under this Section 10.4(h), then Intrexon shall so notify Synthetic
and Synthetic shall not make such assignment or grant such sublicense (or cause it to be made or granted).

 

(i)                
Remaining Materials. At the request of Intrexon, Synthetic shall transfer to Intrexon all quantities of
Reverted Product (including active pharmaceutical ingredient or work-in-process) in the possession of Synthetic or its Affiliates.
Synthetic shall transfer to Intrexon all such quantities of Reverted Products without charge, except that Intrexon shall pay the
reasonable costs of shipping.

 

(j)                
Third Party Vendors. At Intrexon’s request, Synthetic shall promptly provide to Intrexon copies
of all agreements between Synthetic or its Affiliates and Third Party suppliers, vendors, or distributors that relate to the supply,
sale, or distribution of Reverted Products in the Territory. At Intrexon’s request, Synthetic shall promptly: (A) with respect
to such Third Party agreements relating solely to the applicable Reverted Products and permitting assignment, immediately assign
(or cause to be assigned), such agreements to Intrexon, and (B) with respect to all other such Third Party agreements, Synthetic
shall reasonably cooperate to assist Intrexon in obtaining the benefits of such agreements. Synthetic shall be liable for any costs
associated with assigning a Third Party agreement to Intrexon or otherwise obtaining the benefits of such agreement for Intrexon,
to the extent such costs are directly related to Synthetic’s breach. For the avoidance of doubt, Intrexon shall have no obligation
to assume any of Synthetic’s obligations under any Third Party agreement.

 

(k)              
Commercialization. Intrexon shall have the right to develop and commercialize the Reverted Products itself
or with one or more Third Parties, and shall have the right, without obligation to Synthetic, to take any such actions in connection
with such activities as Intrexon (or its designee), at its discretion, deems appropriate.

 

    	41

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

(l)                
Confidential Information. Each Party shall promptly return, or at the other Party’s
request destroy, any Confidential Information of the other Party in such Party’s possession or control at the time of termination;
provided, however, that each Party shall be permitted to retain (i) a single copy of each item of Confidential Information of the
other Party in its confidential legal files for the sole purpose of monitoring and enforcing its compliance with Article 7, (ii)
Confidential Information of the other Party that is maintained as archive copies on the recipient Party’s disaster recovery
and/or information technology backup systems, or (iii) Confidential Information of the other Party necessary to exercise such Party’s
rights in Retained Products (in the case of Synthetic) or Reverted Products (in the case of Intrexon). The recipient of Confidential
Information shall continue to be bound by the terms and conditions of this Agreement with respect to any such Confidential Information
retained in accordance with this Section 10.4(l).

 

10.5              
Surviving Obligations. Termination or expiration of this Agreement shall not affect any rights of either
Party arising out of any event or occurrence prior to termination, including, without limitation,
any obligation of Synthetic to pay any amount which became due and payable under the terms and conditions of this Agreement prior
to expiration or such termination. The following portions of this Agreement shall survive termination or expiration of this Agreement:
Sections 3.1 (as applicable with respect to 10.4(b), 5.5, 5.7, 6.1, 6.2 (with subsection (c) surviving only to the extent relating
to Intrexon Patents that are relevant to Retained Products that, to Intrexon’s knowledge, are being developed or commercialized
at such time, if any), 7.1, 7.2, 7.4, 7.5, 10.4, and 10.5; Articles 9, 11, and 12; and any relevant definitions in Article 1. Further,
Article 7 and Sections 4.5(a), 4.5(c), 5.2 through 5.8, and 9.5 will survive termination of this Agreement to the extent there
are applicable Retained Products.

 

ARTICLE
11

Dispute Resolution

 

11.1              
Disputes. It is the objective of the Parties to establish procedures to facilitate the resolution of disputes
arising under this Agreement in an expedient manner by mutual cooperation and without resort to litigation. In the event of any
disputes, controversies or differences which may arise between the Parties out of or in relation to or in connection with this
Agreement (other than disputes arising from a Committee), including, without limitation, any alleged failure to perform, or breach,
of this Agreement, or any issue relating to the interpretation or application of this Agreement, then upon the request of either
Party by written notice, the Parties agree to meet and discuss in good faith a possible resolution thereof, which good faith efforts
shall include at least one in-person meeting between the Executive Officers of each Party. If the matter is not resolved within
thirty (30) days following the written request for discussions, either Party may then invoke the provisions of Section 11.2. For
the avoidance of doubt, any disputes, controversies or differences arising from a Committee pursuant to Article 2 shall be resolved
solely in accordance with Section 2.4.

 

    	42

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

11.2              
Arbitration. Any dispute, controversy, difference or claim which may arise between the Parties and not
from a Committee, out of or in relation to or in connection with this Agreement (including, without limitation, arising out of
or relating to the validity, construction, interpretation, enforceability, breach, performance, application or termination of this
Agreement) that is not resolved pursuant to Section 11.1 shall, subject to Section 11.10, be settled by binding “baseball
arbitration” as follows. Either Party, following the end of the thirty (30) day period referenced in Section 11.1, may refer
such issue to arbitration by submitting a written notice of such request to the other Party, with the arbitration to be held in
the state where the other Party’s principal office is located (or some other place as may be mutually agreed by the Parties).
Promptly following receipt of such notice, the Parties shall meet and discuss in good faith and seek to agree on an arbitrator
to resolve the issue, which arbitrator shall be neutral and independent of both Parties and all of their respective Affiliates,
shall have significant experience and expertise in licensing and partnering agreements in the pharmaceutical and biotechnology
industries, and shall have some experience in mediating or arbitrating issues relating to such agreements. If the Parties cannot
agree on a single arbitrator within fifteen (15) days of request by a Party for arbitration, then each Party shall select an arbitrator
meeting the foregoing criteria and the two (2) arbitrators so selected shall select within ten (10) days of their appointment a
third arbitrator meeting the foregoing criteria. Within fifteen (15) days after an arbitrator(s) is selected (in the case of the
three-person panel, when the third arbitrator is selected), each Party will deliver to both the arbitrator(s) and the other Party
a detailed written proposal setting forth its proposed terms for the resolution for the matter at issue (the “Proposed
Terms” of the Party) and a memorandum (the “Support Memorandum”) in support thereof. The Parties will
also provide the arbitrator(s) a copy of this Agreement, as it may be amended at such time. Within fifteen (15) days after receipt
of the other Party’s Proposed Terms and Support Memorandum, each Party may submit to the arbitrator(s) (with a copy to the
other Party) a response to the other Party’s Support Memorandum. Neither Party may have any other communications (either
written or oral) with the arbitrator(s) other than for the sole purpose of engaging the arbitrator or as expressly permitted in
this Section 11.2; provided that, the arbitrator(s) may convene a hearing if the arbitrator(s) so chooses to ask questions of the
Parties and hear oral argument and discussion regarding each Party’s Proposed Terms. Within sixty (60) days after the arbitrator’s
appointment, the arbitrator(s) will select one of the two Proposed Terms (without modification) provided by the Parties that he
or she believes is most consistent with the intention underlying and agreed principles set forth in this Agreement. The decision
of the arbitrator(s) shall be final, binding, and unappealable. For clarity, the arbitrator(s) must select as the only method to
resolve the matter at issue one of the two sets of Proposed Terms, and may not combine elements of both Proposed Terms or award
any other relief or take any other action.

 

11.3              
Governing Law. This Agreement shall be governed by and construed under the substantive laws of the State
of New York, excluding any conflicts or choice of law rule or principle that might otherwise refer construction or interpretation
of this Agreement to the substantive law of another jurisdiction.

 

    	43

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

11.4              
Award. Any award to be paid by one Party to the other Party as determined by the arbitrator(s) as set
forth above under Section 11.2 shall be promptly paid in United States dollars free of any tax, deduction or offset; and any costs,
fees or taxes incident to enforcing the award shall, to the maximum extent permitted by law, be charged against the losing Party.
Each Party agrees to abide by the award rendered in any arbitration conducted pursuant to this Article 11, and agrees that, subject
to the United States Federal Arbitration Act, 9 U.S.C. §§ 1-16, judgment may be entered upon the final award in any United
States District Court located in New York and that other courts may award full faith and credit
to such judgment in order to enforce such award. The award shall include interest from the date of any damages incurred for breach
of the Agreement, and from the date of the award until paid in full, at a rate fixed by the arbitrator(s).
With respect to money damages, nothing contained herein shall be construed to permit the arbitrator(s)
or any court or any other forum to award consequential, incidental, special, punitive or exemplary damages. By entering into this
agreement to arbitrate, the Parties expressly waive any claim for consequential, incidental, special, punitive or exemplary damages.
The only damages recoverable under this Agreement are direct compensatory damages.

 

11.5              
Costs. Each Party shall bear its own legal fees. The arbitrator(s) shall assess his or her costs, fees
and expenses against the Party losing the arbitration.

 

11.6              
Injunctive Relief. Nothing in this Article 11 will preclude either Party from seeking equitable relief
or interim or provisional relief from a court of competent jurisdiction, including a temporary restraining order, preliminary injunction
or other interim equitable relief, concerning a dispute either prior to or during any arbitration if necessary to protect the interests
of such Party or to preserve the status quo pending the arbitration proceeding. Specifically, the Parties
agree that a material breach by either Party of its obligations in Section 3.5 or Article 7 of this Agreement may cause irreparable
harm to the other Party, for which damages may not be an adequate remedy. Therefore, in addition to its rights and remedies otherwise
available at law, including, without limitation, the recovery of damages for breach of this Agreement, upon an adequate showing
of material breach of such Section 3.5 or Article 7, and without further proof of irreparable harm other than this acknowledgement,
such non-breaching Party shall be entitled to seek (a) immediate equitable relief, specifically including, but not limited to,
both interim and permanent restraining orders and injunctions, without bond, and (b) such other and further equitable relief as
the court may deem proper under the circumstances. For the avoidance of doubt, nothing in this Section 11.6 shall otherwise limit
a breaching Party’s opportunity to cure a material breach as permitted in accordance with Section 10.2.

 

11.7              
Confidentiality. The arbitration proceeding shall be confidential and the arbitrator(s) shall issue appropriate
protective orders to safeguard each Party’s Confidential Information. Except as required by law, no Party shall make (or
instruct the arbitrator(s) to make) any public announcement with respect to the proceedings or decision of the arbitrator(s) without
prior written consent of the other Party. The existence of any dispute submitted to arbitration, and the award, shall be kept in
confidence by the Parties and the arbitrator(s), except as required in connection with the enforcement of such award or as otherwise
required by applicable law.

 

    	44

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

11.8              
Survivability. Any duty to arbitrate under this Agreement shall remain in effect and be enforceable after
termination of this Agreement for any reason.

 

11.9              
Jurisdiction. For the purposes of this Article 11, the Parties acknowledge their diversity and agree to
accept the jurisdiction of any United States District Court located in New York for the purposes
of enforcing or appealing any awards entered pursuant to this Article 11 and for enforcing the agreements reflected in this Article
11 and agree not to commence any action, suit or proceeding related thereto except in such courts.

 

11.10          
Patent Disputes. Notwithstanding any other provisions of this Article 11, and subject to the provisions
of Section 6.2, any dispute, controversy or claim relating to the scope, validity, enforceability or infringement of any Intrexon
Patents shall be submitted to a court of competent jurisdiction in the country in which such Patent was filed or granted.

 

ARTICLE
12

General Provisions

 

12.1              
Use of Name. No right, express or implied, is granted by this Agreement to either Party to use in any
manner the name of the other or any other trade name or trademark of the other in connection with the performance of this Agreement,
except that (a) either Party may use the name of the other Party as required by regulations and in press releases accompanying
quarterly and annual earnings reports approved by the issuer’s Board of Directors, and (b) Synthetic may use the Intrexon
Trademarks in accord with licenses and restrictions set forth herein.

 

12.2              
LIMITATION OF LIABILITY. NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY SPECIAL, CONSEQUENTIAL, INCIDENTAL,
PUNITIVE, OR INDIRECT DAMAGES ARISING FROM OR RELATING TO ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY
OF SUCH DAMAGES. NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS PARAGRAPH IS INTENDED TO LIMIT OR RESTRICT THE INDEMNIFICATION
RIGHTS OR OBLIGATIONS OF ANY PARTY UNDER ARTICLE 9, OR DAMAGES AVAILABLE FOR BREACHES OF THE OBLIGATIONS SET FORTH IN ARTICLE 7.

 

12.3              
Independent Parties. The Parties are not employees or legal representatives of the other Party for any
purpose. Neither Party shall have the authority to enter into any contracts in the name of or on behalf of the other Party. This
Agreement shall not constitute, create, or in any way be interpreted as a joint venture, partnership, or business organization
of any kind.

 

    	45

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

12.4              
Notice. All notices, including notices of address change, required or permitted to be given under this
Agreement shall be in writing and deemed to have been given when delivered if personally delivered or sent by facsimile (provided
that the party providing such notice promptly confirms receipt of such transmission with the other party by telephone), on the
business day after dispatch if sent by a nationally-recognized overnight courier and on the third business day following the date
of mailing if sent by certified mail, postage prepaid, return receipt requested. All such communications shall be sent to the address
or facsimile number set forth below (or any updated addresses or facsimile number communicated to the other Party in writing):

 

	
        If to Intrexon:

         

         

         

         

         

        with a copy to:
	
        Intrexon Corporation

        20358 Seneca Meadows Parkway

        Germantown, MD 20876

        Attention: President, Protein Production Division

        Fax: (301) 556-9901

         

        Intrexon Corporation

        20358 Seneca Meadows Parkway

        Germantown, MD 20876

        Attention: Legal Department

        Fax: (301) 556-9902

         

	
         

        If to Synthetic:

         

         

         

         

         

        with a copy to:
	
         

        Synthetic Biologics, Inc.

        617 Detroit Street, Suite 100

        Ann Arbor, MI 48104

        Attention: Chief Executive Officer

        Fax: (734) 332-7878

         

        Gracin & Marlow, LLP

        405 Lexington Avenue

        New York, NY 10174

        Attn: Leslie Marlow, Esq.

        Fax: (212) 208-4657

         

12.5              
Severability. In the event any provision of this Agreement is held to be invalid or unenforceable, the
valid or enforceable portion thereof and the remaining provisions of this Agreement will remain in full force and effect.

 

12.6              
Waiver. Any waiver (express or implied) by either Party of any breach of this Agreement shall not constitute
a waiver of any other or subsequent breach.

 

12.7              
Entire Agreement; Amendment. This Agreement, including any exhibits attached hereto, constitute the entire,
final, complete and exclusive agreement between the Parties and supersede all previous agreements or representations, written or
oral, with respect to the subject matter of this Agreement (including any prior confidentiality agreement between the Parties).
All information of Intrexon or Synthetic to be kept confidential by the other Party under any prior confidentiality agreement,
as of the Effective Date, shall be maintained as Confidential Information by such other Party under the obligations set forth in
Article 7 of this Agreement. This Agreement may not be modified or amended except in a writing signed by a duly authorized representative
of each Party.

 

    	46

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

12.8              
Non-assignability; Binding on Successors. Any attempted assignment of the rights or delegation of the
obligations under this Agreement shall be void without the prior written consent of the non-assigning or non-delegating Party;
provided, however, that either Party may assign its rights or delegate its obligations under
this Agreement without such consent (a) to an Affiliate of such Party or (b) to its successor
in interest in connection with any merger, acquisition, consolidation, corporate reorganization, or similar transaction, or sale
of all or substantially all of its assets, provided that such assignee agrees in writing to assume and be bound by the assignor’s
obligations under this Agreement. This Agreement shall be binding upon, and inure to the benefit of, the successors, executors,
heirs, representatives, administrators and permitted assigns of the Parties. Notwithstanding the foregoing, in the event that either
Party assigns this Agreement to its successor in interest by way of merger, acquisition, consolidation, corporate reorganization,
or similar transaction, or sale of all or substantially all of its assets (whether this Agreement is actually assigned or is assumed
by such successor in interest or its affiliate by operation of law (e.g., in the context of a reverse triangular merger)), the
intellectual property rights of such successor in interest or any of its Affiliates other than those licensed in this Agreement
shall be automatically excluded from the rights licensed to the other Party under this Agreement.

 

12.9              
Force Majeure. Neither Party shall be liable to the other for its failure to perform any of its obligations
under this Agreement, except for payment obligations, during any period in which such performance is delayed because rendered impracticable
or impossible due to circumstances beyond its reasonable control, including without limitation earthquakes, governmental regulation,
fire, flood, labor difficulties, civil disorder, acts of terrorism and acts of God, provided that the Party experiencing the delay
promptly notifies the other Party of the delay.

 

12.10          
No Other Licenses. Neither Party grants to the other Party any rights or licenses in or to any intellectual
property, whether by implication, estoppel, or otherwise, except to the extent expressly provided for under this Agreement.

 

12.11          
Non-Solicitation. During the Term and for a period of one (1) year following the end of the Term, neither
Synthetic nor Intrexon may directly or indirectly solicit in order to offer to employ, engage in any discussion regarding employment
with, or hire any employee of the other Party or an individual who was employed by the other party with one (1) year prior to such
solicitation, discussion, or hire, without the prior approval of such other Party. General employment solicitations or advertisements
shall not be considered direct or indirect solicitations, and are not prohibited under this Agreement.

 

    	47

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

12.12          
Legal Compliance. The Parties shall review in good faith and cooperate in taking such actions to ensure
compliance of this Agreement with all applicable laws.

 

12.13          
Counterparts. This Agreement may be executed in any number of counterparts (including by facsimile, PDF,
or other means of electronic communication), each of which taken together will constitute one and the same instrument, and any
of the Parties hereto may execute this Agreement by signing any such counterpart.

 

[Remainder of page intentionally left
blank.]

 

    	48

    	 

    

EXECUTION COPY

CONFIDENTIAL

Portions herein identified by [*****]
have been omitted pursuant to a request for confidential treatment under Rule 24b-2 of the Securities Exchange Act of 1934, as
amended.  A complete copy of this document has been filed separately with the Securities and Exchange Commission.

 

 

In
Witness Whereof, the Parties hereto have duly executed this Exclusive Channel Collaboration Agreement.

 

 

 

	
        Intrexon
        Corporation

         

        By:/s/ Saiid Zarrabian

         

        Name: Saiid Zarrabian

         

        Title: President of Protein Production
Division and Senior Vice President
	
        Synthetic
        Biologics, Inc.

         

        By:/s/Jeffrey Riley

         

        Name: Jeffrey Riley

         

        Title: Chief Executive Officer,
President, and Director

         

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

 

SIGNATURE PAGE FOR EXCLUSIVE CHANNEL COLLABORATION
AGREEMENT

 

    	49

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00206-of-00352.parquet"}]]